Page last updated: 2024-08-23

pirfenidone and Cryptogenic Fibrosing Alveolitis

pirfenidone has been researched along with Cryptogenic Fibrosing Alveolitis in 473 studies

Research

Studies (473)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (0.63)	29.6817
2010's	342 (72.30)	24.3611
2020's	128 (27.06)	2.80

Authors

Authors	Studies
Bast, A; den Hartog, GJM; Gzella, A; Kaminskyy, D; Lelyukh, M; Lesyk, R; Wojtyra, M	1
Liou, JP; Liu, YM; Nepali, K	1
Annoot, D; Auberval, M; Bienvenu, N; Blanque, R; Bock, X; Brys, R; Cherel, L; Christophe, T; Cottereaux, C; Desroy, N; Grassot, JM; Heckmann, B; Housseman, C; Hrvacic, B; Joncour, A; Labeguere, V; Lamers, M; Le Tallec, S; Mollat, P; Monjardet, A; Oste, L; Peixoto, C; Picolet, O; Ralic, J; Roncoroni, V; Rondet, E; Triballeau, N; van der Aar, E; Vandervoort, N; Wakselman, E	1
Chen, X; Du, T; Fu, R; Ji, M; Jin, J; Li, Y; Lin, S; Liu, Y; Sheng, L; Tian, H; Wang, M; Wu, D; Xu, H; Zhang, J; Zhang, K; Zhang, Y	1
Chen, L; Li, Y; Liu, K; Ma, T; Ma, X; Sun, H; Sun, X; Wang, C; Zheng, X; Zhu, Y	1
Huang, MX; Jiang, MY; Le, ML; Luo, HB; Tian, YJ; Wu, Y; Zhang, B; Zhang, C; Zhang, SR	1
Allart, B; Borgonovi, M; Brys, R; Christophe, T; Clément-Lacroix, P; Coornaert, B; Duys, I; El Bkassiny, S; Heckmann, B; Houvenaghel, N; Jans, M; Jaunet, A; Joannesse, C; Mammoliti, O; Menet, C; Oste, L; Palisse, A; Sanière, L; Sonck, K; Wakselman, E	1
Chen, J; Han, C; Huang, MX; Li, Z; Liu, RD; Luo, HB; Tian, YJ; Wu, Y; Xie, X; Yang, YY; Yuan, Y	1
Jiang, Y; Li, N; Li, X; Liang, J; Wang, N; Yang, C; Yang, G; Zhang, K; Zhou, H	1
Kang, J; Song, JW	1
Ishibashi, F; Mizobuchi, T; Nagato, K; Saiki, A; Sugano, I; Tsuyusaki, J	1
Çilli, A; Coşkun, F; Hanta, İ; Ödemiş, A; Sevinç, C; Ursavaş, A	1
Acat, M; Oner, S; Turan, MK; Yildiz Gulhan, P	1
Kreuter, M; Marijic, P; Ruhnke, T; Schwarzkopf, L; Schwettmann, L; Trudzinski, F	1
Aimo, A; Bayes-Genis, A; Emdin, M; Lupón, J; Panichella, G; Spitaleri, G	1
Chambers, DC; Corte, TJ; Cox, IA; de Graaff, B; Glaspole, I; Moodley, Y; Palmer, AJ; Teoh, A; Walters, EH	1
Li, L; Wang, Y; Zang, C; Zheng, Y	1
Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A	1
Amselem, S; Bonniaud, P; Cadranel, J; Chevereau, M; Clément, A; Cottin, V; Crestani, B; Dufaure-Garé, I; Gondouin, A; Guéguen, S; Israël-Biet, D; Jouneau, S; Marchand-Adam, S; Nunes, H; Reynaud-Gaubert, M; Wemeau, L	1
Brunetti, ND; Casparrini, M; Correale, M; Foschino Barbaro, MP; Lacedonia, D; Scioscia, G; Simone, F; Stornelli, SR; Tricarico, L	1
Cordova, FC; Criner, GJ; Dorey-Stein, ZL; Galli, JA; Shapiro, W; Zhao, H	1
Chen, F; Huo, J; Li, S; Meng, Y; Tang, Q; Tian, L; Wang, W; Yang, Q	1
Abdelaziz, A; Dutta, P; Finnerty, JP; Kamil, H; Ponnuswamy, A	1
Gil, BM; Heo, JW; Hong, Y; Kang, HS; Kim, YH; Kwon, SS; Lee, EG; Lee, TH; Ryoo, J	1
Liu, X; Qiu, L; Wu, J; Wu, W; Zhang, G	1
Borah, BJ; Dempsey, TM; Limper, AH; Moriarty, JP; Thao, V	1
Hachisu, Y; Hisada, T; Koga, Y; Kouno, S; Maeno, T; Nakagawa, J; Saito, Y; Sawada, Y; Shin, Y; Sunaga, N; Takehara, K; Umetsu, K; Utsugi, M; Wakamatsu, I; Yatomi, M; Yoshimi, S	1
Borsino, C; Mazzoleni, L; Zovi, A	1
Ashish, S; Chanda, D; Chiles, J; Kumar, PL; McDonald, MN; Mobley, JA; Neptune, ER; Thannickal, VJ; Wilson, AC	1
Bastías O, C; Díaz B, I; Reyes C, F; Rodriguez M, K	1
Baart, S; Grutters, JC; Lie, NSL; Miedema, JR; Moor, CC; Mostard, RLM; Veltkamp, M; Wijsenbeek, MS	1
Wells, AU	2
Baba, T; Ikeda, S; Iwasawa, T; Katano, T; Kato, T; Kitamura, H; Oda, T; Ogura, T; Okuda, R; Sekine, A; Shintani, R; Tabata, E; Takemura, T; Yamakawa, H	1
Alonso-Gómez, A; Carrón-Herrero, A; León-Román, F	1
Chiba, H; Kameda, M; Kobayashi, T; Kuronuma, K; Morioka, Y; Otsuka, M; Takahashi, H; Wakabayashi, M; Yoshioka, T	1
Bouzillé, G; Fournier, D; Jouneau, S; Osmont, MN; Polard, E; Scailteux, LM	1
Dušek, L; Gregor, J; Hájková, M; Jovanović, D; Kirchgässler, KU; Kramer, MR; Lewandowska, K; Littnerová, S; Májek, O; Mogulkoć, N; Müller, V; Šterclová, M; Stoeva, N; Studnicka, M; Tekavec-Trkanjec, J; Vašáková, MK	1
Behera, D; Deep, A; Gupta, S; Padhan, P; Priyadarshini, S; Singh, P	1
Cho, YJ; Kim, HJ; Kim, TH; Kim, YW; Kwon, BS; Lee, CT; Lee, JH; Lee, YJ; Lim, SY; Park, JS; Shin, YY; Song, MJ	1
Kang, JH; Kim, DW; Kwon, TK; Park, CW; Yang, MS	1
Belhassen, M; Bonniaud, P; Cottin, V; Dalon, F; Kirchgässler, KU; Nolin, M; Spagnolo, P; Van Ganse, E	1
Ahir, M; Bonnen, MD; Ebrahimpour, A; Eissa, NT; Ghebre, YT; Jegga, AG; Montesi, SB; Raghu, G; Wang, M	1
Caplazi, P; Ding, N; Gierke, S; LaCanna, R; Ma, HY; Moffat, J; N'Diaye, EN; Uttarwar, S; Vander Heiden, JA; Wolters, PJ; Xi, Y	1
Cho, HS; Chung, C; Kim, HC; Kim, J	1
Barczyk, A; Chaudhuri, N; Corte, TJ; Freeman, L; Glaspole, I; Grainge, C; Hopkins, P; Jassem, E; Montgomery, AB; Nair, D; Otto, K; Piotrowski, W; Raghu, G; Shaffer, ML; Šterclová, M; Veale, A; West, A; Wijsenbeek, MS; Wilsher, ML	1
Crooks, JL; Fernández Pérez, ER; Fier, K; Groshong, SD; Humphries, SM; Koelsch, TL; Lynch, DA; Mohning, MP; Solomon, JJ; Swigris, JJ	1
Brown, KK; Costabel, U; Cottin, V; Danoff, SK; Fieuw, A; Ford, P; Groenveld, I; Helmer, E; Jenkins, RG; Jentsch, G; Kreuter, M; Maher, TM; Milner, J; Molenberghs, G; Penninckx, B; Prasad, N; Randall, MJ; Rocak, S; Seghers, I; Shao, L; Taneja, A; Van Den Blink, B; Vandenrijn, C; Verbruggen, N; Watkins, TR; Wijsenbeek, MS; Wuyts, WA	1
Gower, WA; Hagood, JS; McKinzie, CJ; Vece, TJ	1
Cai, H; Cao, M; Gao, Y; Jiang, H; Ma, M; Qiu, X	1
Aliberti, S; Amati, F; Blasi, F; Gramegna, A; Mantero, M; Polelli, V; Stainer, A	1
Gao, H; Gong, B; Gong, T; Huang, Y; Luo, S; Zhang, L; Zhang, R; Zhao, T	1
Albera, C; Alvaro, G; Behr, J; Costabel, U; Gilberg, F; Glassberg, MK; Haller, H; Lancaster, L; Nathan, SD; Samara, K; Wuyts, WA	1
Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO	1
Antoniou, K; Avilés, V; Bachs, A; Bermudo, G; Bonella, F; Maher, TM; Molina-Molina, M; Montes-Worboys, A; Palma, J; Renzoni, E; Rigo-Bonnin, R; Rivera-Ortega, P; Russell, AM; Shull, JG; Suarez-Cuartin, G; Tebé, C; Vancheri, A; Vancheri, C; Vicens-Zygmunt, V; Wijsenbeek, M	1
Jo, YS; Kim, KJ; Kim, YH; Rhee, CK	1
Cao, Y; Zhang, XL; Zheng, B	1
Colquitt, JL; Loveman, E; O'Reilly, K; Scott, DA	1
Chou, W; Glassberg, MK; Lin, CY; Morgenthien, EA; Nathan, SD; Noble, PW; Stauffer, JL	1
Morrow, T	3
Glassberg, MK	1
Bast, A; Drent, M; Elfferich, MDP; Jessurun, NT; Proesmans, VLJ; Wijnen, PAHM	1
Albera, C; Ghirardini, A; Harari, S; Kirchgaessler, KU; Luppi, F; Pesci, A; Rogliani, P; Rottoli, P; Sebastiani, A; Tavanti, L; Tomassetti, S; Vancheri, C	1
Enomoto, N; Fujisawa, T; Furuhashi, K; Hashimoto, D; Hozumi, H; Inui, N; Karayama, M; Kobayashi, T; Kono, M; Koyanagi, Y; Miki, Y; Miyashita, K; Nakamura, H; Nakamura, Y; Saito, G; Suda, T; Suzuki, Y; Tsutsumi, A; Yasui, H	1
Huang, H; Li, S; Shao, C; Sun, YX; Xu, K; Xu, ZJ	1
Chaudhuri, N; Kahn, N; Kreuter, M; Müller, V; Somogyi, V; Torrisi, SE	1
Bocchino, M; Boschetto, P; Casillo, V; Cerri, S; Ciervo, A; Flacco, ME; Luppi, F; Manno, M; Manzoli, L; Stendardo, M	1
Maher, TM; Strek, ME	1
Chen, X; Foda, HD; Hasaneen, NA; Smaldone, GC; Vu, TN	1
Culver, DA; Glennie, J; Li, M; Olman, MA; Perelas, A; Scheraga, RG; van Kerkhove, K	1
Kolb, MR; Wongkarnjana, A; Yanagihara, T	1
Collins, BF; Raghu, G	1
Bartley, K; Bondue, B; Compere, C; Dahlqvist, C; Gusbin, N; Kirchgaessler, KU; Lee, YC; Maddens, S; Schlesser, M; Slabbynck, H; Wuyts, WA	1
Bacchi Reggiani, ML; Bandelli, G; Bassi, I; Betti, S; Carpano, M; Cerri, S; Clini, E; Donatelli, P; Garuti, M; Guerrieri, A; Luppi, F; Monari, M; Nava, S; Tonelli, R	1
Imanishi, N; Kanayama, M; Kuroda, K; Kuwata, T; Matsumiya, H; Mori, M; Shinohara, S; Taira, A; Tanaka, F; Yoneda, K	1
Buendía-Roldan, I; Castillo-Castillo, K; Castillo-Pedroza, J; Estrada, A; Gaxiola, M; Mateos-Toledo, H; Mejía-Ávila, M; Mejía-Hurtado, JG; Rodríguez-Barreto, Ó; Rojas-Serrano, J; Selman, M	1
Beck, S; Bischof, RJ; Davies, AN; Ibrahim, J; Kaminskas, LM; Landersdorfer, CB; Leong, N; Montgomery, AB; Pham, S; Surber, MW	1
Fang, C; Ferianc, M; Guo, J; Huang, H; Xu, Z	1
Chiba, H; Ikeda, K; Kuronuma, K; Mori, Y; Nishikiori, H; Otsuka, M; Takahashi, H; Umeda, Y; Yoshikawa, T	1
Flaherty, KR; Freiheit, EA; Holtze, CH; Kim, HJ; Limb, SL; Pan, WT; Raimundo, K; Stauffer, JL	1
Higo, H; Ichikawa, H; Itano, J; Kajimoto, K; Kanehiro, A; Kayatani, H; Kiura, K; Maeda, Y; Miyahara, N; Oda, N; Senoo, S; Shibayama, T; Taniguchi, A; Tanimoto, Y; Watanabe, H	1
Aokage, K; Ishii, G; Miyoshi, T; Sekihara, K; Tane, K; Tsuboi, M	1
Calvello, M; Cerri, S; Donatelli, P; Iovene, B; Lo Greco, E; Luppi, F; Pavone, M; Richeldi, L; Sgalla, G; Vancheri, A; Vancheri, C; Varone, F	1
Chung, MP; Jegal, Y; Kim, YS; Kim, YW; Lee, HB; Oh, IJ; Park, JS; Park, MS; Song, JW; Uh, ST	1
Bocchino, M; Caminati, A; Faverio, P; Fumagalli, A; Gasbarra, M; Iovino, P; Petruzzi, A; Sanduzzi, A; Scalfi, L; Sebastiani, A; Stanziola, AA	1
Aerts, JGJV; Bresser, P; Chavannes, NH; Grutters, JC; Moor, CC; Mostard, RLM; Wijsenbeek, MS	1
Beers, MF; Duerr, J; Dvornikov, D; Engelmann, TA; Fraumann, SG; Hegermann, J; Herth, FJF; Kawabe, H; Klingmüller, U; Knudsen, L; Konietzke, P; Kreuter, M; Kreutz, C; Leitz, DHW; Mall, MA; Muley, T; Mulugeta, S; Ochs, M; Rotin, D; Seyhan Agircan, A; Szczygiel, M; Wielpütz, MO; Zadora, PK	1
Białas, AJ; Buchczyk, M; Gomółka, P; Górska, K; Jagielska-Len, H; Jarzemska, A; Jassem, E; Jastrzębski, D; Kania, A; Koprowski, M; Krenke, R; Kuś, J; Lewandowska, K; Majewski, S; Martusewicz-Boros, MM; Piotrowski, WJ; Roszkowski-Śliż, K; Siemińska, A; Sobiecka, M; Szewczyk, K; Sładek, K; Tomczak, M; Tomkowski, W; Wiatr, E; Ziora, D; Żołnowska, B	1
Kreuter, M; Luppi, F; Moor, CC; Wuyts, WA	1
Bonella, F; Kreuter, M; Li, X; Oltmanns, U; Peng, S; Shi, H; Wei, L; Yin, D	1
Andrade Cabrera, C; Benites Solis, J; Briones Claudett, KH; Briones Claudett, MH; Grunauer Andrade, M; Rodriguez Garcia, S; Vargas Domenica, E	1
Angibaud, A; Chauvin, P; Diridollou, T; Gaignon, T; Jouneau, S; Kerjouan, M; Lederlin, M; Lemerre, J; Rousseau, C; Salé, A; Sohier, L; Tas, M	1
Kahn, N; Kreuter, M; Torrisi, SE; Vancheri, C	1
Boulate, D; Crutu, A; Dauriat, G; Dolidon, S; Fabre, D; Fadel, E; Feuillet, S; Florea, V; Gazengel, P; Hanna, A; Le Pavec, J; Mercier, O; Mitilian, D; Mussot, S; Pradere, P	1
Franciosa, C; Richeldi, L; Sgalla, G; Simonetti, J	1
Adegunsoye, A; Alqalyoobi, S; Bowman, WS; Haczku, A; Lee, CT; Linderholm, A; Ma, SF; Noth, I; Oldham, JM; Pugashetti, JV; Sarma, N; Sperling, A; Strek, ME	1
Agarwala, P; DeLeon, J; Glass, AD; Glass, DS; Grossfeld, D; Kasselman, LJ; Reiss, AB; Renna, HA; Spiegler, P	1
Chicharro, P; de Argila, D; Muñoz-Aceituno, E; Reolid, A; Rodríguez-Jiménez, P	1
Bonella, F; Maher, TM; Ryerson, CJ; Spagnolo, P; Tzouvelekis, A	1
Fellrath, JM	1
Condos, R; Deshwal, H; Gibson, CD; Kugler, MC; Munger, JS	1
Corral, M; DeYoung, K; Kong, AM	1
Brown, AW; de Andrade, JA; Flaherty, KR; Kaner, RJ; King, CS; Nathan, SD; Noth, I; Padilla, ML; Rahaghi, FF; Safdar, Z; Scholand, MB; Shifren, A	1
Antoniou, K; Kamekis, A; Kokosi, M; Swigris, JJ; Symvoulakis, EK	1
Aerts, JGJV; Bresser, P; Dirksen, CD; Grutters, JC; Kimman, ML; Moor, CC; Mostard, RLM; Wijsenbeek, MS	1
Bando, M; Hattori, N; Homma, S; Inase, N; Johkoh, T; Kataoka, K; Kato, M; Kishaba, T; Kishi, K; Kondoh, Y; Kuwano, K; Mukae, H; Nishioka, Y; Okamoto, M; Saito, T; Sakai, F; Sakamoto, S; Sasaki, S; Suda, T; Taguchi, Y; Takizawa, H; Tanino, Y; Yatera, K	1
Beloki, L; Carruthers, A; Chahboub, A; Clarke, D; Dunmore, R; Güler-Gane, G; Koch, S; Kuziora, M; Lewis, A; Liarte Marin, E; May, R; Miranda, E; Murray, L; Overed-Sayer, C; Parfrey, H; Rassl, D	1
Antoniou, K; Behr, J; Bengus, M; Bouros, DE; Gilberg, F; Guiot, J; Harari, S; Kirchgaessler, KU; Kramer, MR; Mogulkoc Bishop, N; Nathan, SD; Perjesi, A; Wells, AU; Wuyts, WA	1
Apel, RM; Bengel, FM; Derlin, T; Freise, J; Jaeger, B; Jonigk, D; Prasse, A; Ross, TL; Seeliger, B; Shin, HO; Warnecke, G; Weiberg, D; Welte, T; Wester, HJ	1
Broder, MS; Chang, E; Corral, M; Gokhale, S; Reddy, SR	1
Bi, Y; Chen, J; Chowdhury, BA; Karimi-Shah, BA; Marathe, A; Paterniti, MO; Rekić, D; Wang, Y	1
Akazawa, Y; Ishijima, M; Kanazu, M; Kuge, T; Mori, M; Okabe, F; Uenami, T; Yamaguchi, T; Yamamoto, Y; Yano, Y	1
Irfan, M; Trachalaki, A; Wells, AU	1
Arlandis, M; Aznar, T; Chiner, E; Herraiz, P; Marcos Ribes, B; Sancho-Chust, JN; Talens, A	1
Asano, K; Enokida, K; Hattori, S; Hayama, N; Hirabayashi, K; Horio, Y; Ito, Y; Miyaoka, M; Niimi, K; Oguma, T; Ohshinden, K; Takahashi, F; Takahashi, G; Takahashi, M; Takiguchi, H; Takihara, T; Tanaka, J	1
Di Martino, E; Polidori, P; Provenzani, A; Vitulo, P	1
Homma, S; Isobe, K; Isshiki, T; Kurosaki, A; Nakamura, Y; Sakamoto, S; Shimizu, H	1
Agarwal, R; Aggarwal, AN; Bal, A; Behera, D; Dhooria, S; Garg, M; Muth, V; Prasad, KT; Sehgal, IS	1
Barber, CM; Bianchi, SM; Chaudhuri, N; Eaden, JA; Renshaw, SA	1
Azuma, M; Imakura, T; Kagawa, K; Kawano, H; Koyama, K; Murakami, K; Naito, N; Nishimura, H; Nishioka, Y; Sato, S; Shinohara, T; Takahashi, N; Toyoda, Y	1
Dygai, A; Ermakova, N; Krupin, V; Kubatiev, A; Morozov, S; Nebolsin, V; Novikov, F; Pakhomova, A; Pan, E; Pershina, O; Sandrikina, L; Skurikhin, E; Widera, D; Zhukova, M	1
Forbat, E; Parr, D; Shim, TN	1
Ahmad, K; Andrejak, C; Ba, I; Blanchard, E; Bondue, B; Bonniaud, P; Borie, R; Cottin, V; Crestani, B; Froidure, A; Funke-Chambour, M; Gamez, AS; Gondouin, A; Grutters, J; Hirschi, S; Jouneau, S; Justet, A; Kannengiesser, C; Klay, D; Manali, E; Marchand-Adam, S; Molina Molina, M; Naccache, JM; Nunes, H; Papiris, S; Porcher, R; Prévot, G; Reynaud-Gaubert, M; Tromeur, C; van Moorsel, C; Wemeau, L	1
Azuma, A; Chiba, H; Ebina, M; Ikeda, K; Kondoh, Y; Kudoh, S; Miyazawa, S; Nishikiori, H; Nukiwa, T; Ogura, T; Sakaguchi, H; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H	1
Chang, J; Choi, JS; Chung, KS; Jung, JY; Kang, YA; Kim, SY; Kim, YS; Lee, SH; Moon, SW; Park, MS; Song, MJ	1
Aimo, A; Bayes-Genis, A; Egea, OI; Emdin, M	1
Han, H; Huang, Y; Kang, Y; Li, L; Liu, B; Liu, C; Qin, W; Tang, Y; Yuan, X; Zhao, W; Zou, J	1
Dempsey, TM; Limper, AH; Payne, S; Sangaralingham, L; Shah, ND; Yao, X	1
Guler, SA; Lindell, KO; Ryerson, CJ; Swigris, J	1
Baba, T; Hagiwara, E; Ikeda, S; Katano, T; Kitamura, H; Komatsu, S; Misumi, T; Ogura, T; Okabayashi, H; Okuda, R; Sekine, A; Yamakawa, H	1
Ali, MF; Anderson, DK; Aubry, MC; Carmona, EM; Dasari, H; Egan, AM; Kottom, TJ; Limper, AH; Peikert, T; Shaughnessy, GF; Van Keulen, VP; Yi, ES	1
Bodea, C; Cao, S; Karman, J; Levesque, MC; Wang, J	1
Chen, T; Chen, YN; Hu, Y; Huang, Y; Li, HP; Li, QH; Shi, JY; Wang, XD; Weng, D; Wu, CY; Ye, S; Yin, CS; Zhang, AH; Zhang, Y; Zhou, Y	1
Ando, T; Fushimi, K; Hasegawa, W; Jo, T; Matsui, H; Nagase, T; Sakamoto, Y; Uda, K; Urushiyama, H; Yasunaga, H	1
Auriemma, L; Costantini, A; De Vita, F; Di Fabio, C; Di Fabio, L; Esposito, F; Marinari, S; Petragnani, G; Santoleri, F; Spacone, A	1
Comes, A; Richeldi, L; Sgalla, G	1
Khor, YH	1
Chang, J; Jung, JY; Kang, YA; Kim, SY; Kim, YS; Lee, SH; Park, MS; Song, MJ	1
Belhassen, M; Dalon, F; Nolin, M; Van Ganse, E	1
Bando, M; Hara, H; Hashimoto, S; Hisata, S; Homma, S; Inase, N; Izumi, S; Kataoka, K; Kato, M; Mukae, H; Nishioka, Y; Ogura, T; Saito, Y; Sakamoto, S; Shimizu, Y; Tanino, Y; Waseda, Y; Watanabe, K; Yatera, K	1
Lerede, M; Richeldi, L; Sgalla, G	1
Asmani, M; Zhao, R	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Miyazawa, S; Nukiwa, T; Ogura, T; Sakaguchi, H; Sakamoto, K; Suga, M; Sugiyama, Y; Suzuki, A; Taguchi, Y; Takahashi, H	1
Lertjitbanjong, P; Moua, T; Petnak, T; Thongprayoon, C	1
Ando, M; Homma, S; Kishi, K; Ono, H; Sugino, K; Tsuboi, E; Watanabe, N	1
Aono, Y; Enomoto, N; Fujisawa, T; Furuhashi, K; Hasegawa, H; Hozumi, H; Inui, N; Karayama, M; Kono, M; Mori, K; Nakamura, H; Nakamura, Y; Naoi, H; Suda, T; Suzuki, Y; Yokomura, K	1
Dempsey, TM; Kelly, BT; Limper, AH; Moua, T; Payne, SR; Sangaralingham, LR; Shah, ND; Teague, TT; Thao, V	1
Bendstrup, E; Carlson, L; Durheim, MT; Hyldgaard, C; Kalafatis, D; Myllärniemi, M; Sjåheim, T; Sköld, CM; Sutinen, EM	1
Cho, YJ; Choi, SM; Hwang, H; Kim, YW; Lee, CT; Lee, JH; Lee, JK; Lee, YJ; Park, JS; Yoon, HI	1
Criner, GJ; Dass, C; Galli, JA; Pandya, A; Vega-Olivo, M; Zhao, H	1
Dirksen, CD; Gelens, M; Kimman, ML; Mostard, R; Rotteveel, AH; Storm, M; Tak, NC; van de Kar, NCAJ; van Jaarsveld, X; Wetzels, J; Wijnsma, KL; Wijsenbeek, M	1
Bi, Y; Chowdhury, BA; Karimi-Shah, BA; Paterniti, MO; Rekić, D; Wang, Y	1
Bonella, F; Costabel, U; Kirchgässler, KU; Kolb, M; Koschel, D; Kreuter, M; Maher, TM; Renzoni, E; Spagnolo, P; Weycker, D; Wuyts, W	1
Maher, TM; Spagnolo, P	1
Furuya, K; Homma, S; Isshiki, T; Kinoshita, A; Matsumoto, K; Sakamoto, S; Sekiya, M; Shimizu, H; Sugino, K	1
Kitamura, H; Ogura, T	1
Chou, W; Collard, HR; Day, BM; Ley, B; Raimundo, K; Stauffer, JL; Swigris, J	1
Bruni, T; Fabbrizzi, A; Gerardi, RE; Iovene, B; Lo Greco, E; Lombardi, F; Magnini, D; Montemurro, G; Richeldi, L; Tagliaboschi, L	1
Flaherty, KR; Martinez, FJ	1
Alberti, ML; Caro, FM; Fernández, ME; Paulin, F	1
Berardini, L; Leone, PM; Macagno, F; Mari, PV; Panico, L; Richeldi, L; Varone, F	1
Ashton, RW; Sathiyamoorthy, G; Sehgal, S	1
AbuTarif, M; Bax, L; Chan, P; Chen, C; Huang, SP; Rosen, G; Soares, H; Zhang, N	1
Bautista, B; Felton, MK; Malesker, M; Morrow, LE	1
Raghu, G; Richeldi, L	1
Belloni, P; Ding, HT; Pan, L; Putnam, WS; Rubino, CM; Wang, J	1
Beatson, D; Chambers, DC; Chapman, S; Corte, TJ; de Boer, S; Glaspole, I; Goh, N; Grainge, C; Holland, A; Hopkins, P; Jo, HE; Jones, L; Keir, G; Moodley, Y; Reynolds, PN; Troy, LK; Whitford, H; Wilsher, M	1
Chaudhuri, N; Hayton, C	1
Bouros, D; Bouros, E; Tzilas, V; Tzouvelekis, A	1
Abe, M; Ichimura, Y; Ikari, J; Matsumura, A; Matsumura, T; Suzuki, K; Tatsumi, K; Terada, J; Tsushima, K; Yamagishi, K	1
Gao, L; Ren, H; Wang, K; Yang, H	1
Grutters, JC; Kreuter, M; Quaresma, M; Richeldi, L; Ryerson, CJ; Stansen, W; Stowasser, S; Valeyre, D; Vancheri, C; Wiebe, S; Wuyts, WA	1
Albera, C; Costabel, U; Hormel, P; Hulter, HN; Lancaster, LH; Lin, CY; Noble, PW	1
Axmann, J; Bonella, F; Jouneau, S; Maher, TM; Molina-Molina, M; Ripamonti, E; Russell, AM; Vancheri, C	1
Boccabella, C; Comes, A; Condoluci, C; Golfi, N; Inchingolo, R; Mastrobattista, A; Richeldi, L; Smargiassi, A	1
Chiba, H; Hasegawa, Y; Ikeda, K; Kuronuma, K; Nishikiori, H; Otsuka, M; Saito, A; Shiratori, M; Takahashi, H; Yamada, G; Yokoo, K	1
Bonella, F; Kolb, M; Wollin, L	1
Caminati, A; Cassandro, R; Harari, S; Torre, O	1
Raghu, G	2
Adamski, H; Arnouat, B; Droitcourt, C; Dupuy, A; Jouneau, S; Kerjouan, M; Le Garrec, M; Oger, E; Polard, E; Polat, A	1
Nathan, SD	1
Maher, TM	2
Tepede, A; Yogaratnam, D	1
Birring, SS; Cottin, V; Renzoni, E; Russell, AM; van Manen, MJG; Vancheri, C; Vindigni, V; Wapenaar, M; Wijsenbeek, MS	1
Gahl, WA; Gochuico, BR; O'Brien, KJ	1
Kang, H; Kim, JE; Sohn, KM; Woo, YJ	1
Arízaga Maguregui, A; González Larrocha, O; Ortega Mera, U; Romero Rojano, P	1
Corwine, J; Danoff, S; Galiatsatos, P; Silhan, L	1
Tu, M; Wang, Z; Weng, J; Yang, B	1
Albera, C; Costabel, U; de Andrade, JA; Kirchgaessler, KU; Lancaster, LH; Nathan, SD; Padilla, ML; Stauffer, JL; Wijsenbeek, MS; Zibrak, JD	1
D'Arcy, C; De la Harpe Golden, P; Kelly, AS; Lally, A	1
Azuma, A; Gemma, A; Inomata, M; Miura, Y; Nei, T; Saito, T; Saito, Y; Takoi, H; Tanaka, T; Yatagai, Y	1
Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H	1
Bénard, S; Catella, L; Cottin, V; Le Lay, K; Luciani, L; Porte, F	1
Criner, GJ; Vega-Olivo, M	1
Calvello, M; Iovene, B; Ori, M; Richeldi, L; Sgalla, G; Varone, F	1
Epstein Shochet, G; Shitrit, D; Wollin, L	1
Tanino, Y	1
Chiang, B; Kamiya, K; Komine, M; Maekawa, T; Mato, N; Murata, S; Ohtsuki, M; Okada, H; Suda, K	1
Lewandowska, K	1
Balestro, E; Bazzan, E; Biondini, D; Cerri, S; Clini, E; Cocconcelli, E; Cosio, MG; Foschino Barbaro, MP; Gregori, D; Lacedonia, D; Luppi, F; Milaneschi, R; Saetta, M; Spagnolo, P	1
Kapila, A; Moore, CA	1
Dorca, J; Escobar, I; Llatjós, R; Luburich-Hernaiz, P; Machahua-Huamani, C; Molina-Molina, M; Montes-Worboys, A; Sala-Llinas, E; Vicens-Zygmunt, V	1
Abnoos, M; Ashtari, K; Ilka, R; Mehravi, B; Mohseni, M; Mousavi, SAJ	1
Aryal, S; Nathan, SD	1
Behr, J; Bengus, M; Gilberg, F; Harari, S; Kirchgaessler, KU; Nathan, SD; Wells, AU; Wuyts, W	1
Lederer, DJ; Martinez, FJ	1
Fan, YL; Yan, YJ; Ye, Q; Yu, SW	1
Davani, S; Gondouin, A; Moltenis, M; Valnet Rabier, MB	1
Hanada, S; Kishi, K; Miyamoto, A; Mochizuki, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Uruga, H	1
Bengus, M; Fell, CD; Flaherty, KR; Gilberg, F; Huggins, JT; Nunes, H; Petzinger, U; Stauffer, JL; Sussman, R; Valenzuela, C; Wijsenbeek, M	1
Ask, K; Bellaye, PS; Gauldie, J; Granton, E; Hambly, N; Iglarz, M; Imani, J; Kolb, M; Sato, S; Shimbori, C; Upagupta, C; Yanagihara, T	1
Azuma, A; Bando, M; Date, H; Ebina, M; Fukuoka, J; Gemma, A; Goto, Y; Hasegawa, Y; Hattori, N; Homma, S; Inase, N; Inoue, Y; Ishii, Y; Izumi, S; Johkoh, T; Kido, T; Kishaba, T; Kishi, K; Miyamoto, A; Mukae, H; Nakayama, T; Nishioka, Y; Ogura, T; Sakamoto, S; Sasaki, S; Suda, T; Sugino, K; Taguchi, Y; Takahashi, H; Takahashi, K; Taniguchi, H; Watanabe, K; Yokoyama, A; Yoshino, I	1
Carrington, R; Jordan, S; Page, CP; Pitchford, SC	1
Burridge, K; Doerschuk, CM; Monaghan-Benson, E; Wittchen, ES	1
Kreuter, M; Quaresma, M; Richeldi, L; Stowasser, S; Vancheri, C; Wuyts, WA	1
Anand, A; Rajchgot, J; Stanbrook, MB	1
Alberti, ML; Campins, F; Caro, FM; Enghelmayer, JI; Fernández, ME; Lancellotti, D; Papucci, T; Paulin, F; Sebastiani, JA	1
Kreuter, M; Maher, T	1
Arron, JR; Cabanski, CR; Collard, HR; Gu, C; Jia, G; Ley, B; Neighbors, M; Peng, K; Ramalingam, TR; Ray, JM; Sheng, XR; Tew, GW; Wolters, PJ	1
Aichler, M; Burgstaller, G; Eickelberg, O; Fernandez, IE; Feuchtinger, A; Schmitt-Kopplin, P; Sun, N; Verleden, SE; Walch, A; Wei, M; Witting, M	1
Calabrese, F; Lunardi, F; Pezzuto, F; Vuljan, SE	1
Achtar-Zadeh, N; Green, G; Jones, KD; Kukreja, J; Wolters, PJ; Xu, B; Zhang, Y	1
Didiasova, M; Gungl, A; Klepetko, W; Kosanovic, D; Kreuter, M; Kwapiszewska, G; Marsh, LM; Olschewski, A; Olschewski, H; Schaefer, L; Schermuly, RT; Schneider, M; Seeger, W; Sinn, K; Thekkekara Puthenparampil, H; Weiss, B; Wilhelm, J; Wujak, L; Wygrecka, M	1
Azuma, A; Kashiwada, T	1
Alsafadi, HN; Behr, J; Buhl, L; Hermann, S; Hilgendorff, A; Klee, S; Königshoff, M; Lehmann, M; Lindner, M; Mutze, K; Ota, C; Wagner, DE	1
Hays, SR; Jones, KD; Kolaitis, NA; Kukreja, J; Leard, LE	1
Carroll, C; Davis, S; Essat, M; Hamilton, J; Rafia, R	1
Schmutz, JL	1
Kishaba, T	2
Chen, Q; Huang, W; Ma, Z; Shen, Z; Yu, C; Zhang, H; Zhang, Z; Zhao, C	1
Agouni, A; Carru, C; Cossu, A; Fois, AG; Giordo, R; Pintus, G; Pirina, P; Posadino, AM; Rizk, NM; Zinellu, A	1
Buendía-Roldán, I; Mejía, M; Selman, M	1
Funke-Chambour, M; Guler, SA	1
Tzouvelekis, A; Wolters, PJ	1
Antoniou, KM; Bibaki, E; Detorakis, S; Margaritopoulos, GA; Papastratigakis, G; Trachalaki, A; Tzanakis, N; Vasarmidi, E; Wells, AU	1
Costabel, U; Glaspole, I; Glassberg, MK; Lancaster, LH; Lederer, DJ; Limb, SL; Morgenthien, EA; Nathan, SD; Pereira, CA; Trzaskoma, B; Wells, AU	1
Bach, AC; Chillappagari, S; Fink, L; Guenther, A; Klepetko, W; Korfei, M; Krämer, OH; Lasky, JA; MacKenzie, B; Mahavadi, P; Pullamsetti, SS; Ruppert, C; Saito, S; Seeger, W; Skwarna, S; Stelmaszek, D	1
Albert, GR; Cantin, AM; Cesari, F; Gagnon, L; Hagerimana, A; Hernandez, P; Khalil, N; Kolb, M; Laurin, P; Manganas, H; Moran, JE; Parker, JM; Ryerson, CJ; Sawtell, R; Shapera, S; Turcotte, EE	1
Higo, H; Kiura, K; Kurosaki, T; Miyoshi, K; Otani, S; Oto, T; Sugimoto, S; Tanaka, S; Toyooka, S; Yamane, M	1
Bondue, B; Castiaux, A; Doumont, G; Egrise, D; Goldman, S; Huaux, F; Lacroix, S; Mathey, C; Sherer, F; Van Simaeys, G	1
Bartos, V; Binkova, I; Bittenglova, R; Doubkova, M; Homolka, J; Janotova, M; Kervitzer, J; Kolek, V; Kralova, R; Kriegova, E; Lacina, L; Lisa, P; Lnenicka, J; Lostakova, V; Ondrejka, G; Petrik, F; Plackova, M; Psikalova, J; Rihak, V; Snizek, T; Sterclova, M; Strenkova, J; Suldova, H; Svoboda, M; Tyl, R; Vasakova, M; Zurkova, M	1
Agostini, C; Albera, C; Biffi, A; Bocchino, M; Caminati, A; Cerri, S; Cinetto, F; Confalonieri, M; Della Porta, R; Di Michele, L; Harari, S; Luppi, F; Messore, B; Pesci, A; Poletti, V; Puxeddu, E; Refini, RM; Rogliani, P; Rosso, R; Rottoli, P; Salton, F; Sanduzzi Zamparelli, A; Sebastiani, A; Specchia, C; Tomassetti, S; Vancheri, C	1
Blackwell, TS; Kropski, JA	1
Ballester, B; Cortijo, J; Milara, J	1
Heukels, P; Kool, M; Moor, CC; von der Thüsen, JH; Wijsenbeek, MS	1
Bennett, D; Fossi, A; Fui, A; Mazzei, MA; Pieroni, M; Refini, RM; Rottoli, P; Valentini, ML	1
Hewitt, RJ; Maher, TM	1
Albera, C; Costabel, U; Gilberg, F; Glassberg, MK; Kirchgaessler, KU; Lancaster, LH; Noble, PW; Petzinger, U; Wuyts, WA	1
Ferrara, G; Ortiz, C; Pesonen, I	1
Cilli, A; Hanta, I; Sevinc, C	1
Black, KE; Feneis, JF; Mark, EJ; Montesi, SB	1
Behr, J; Ceelen, F; Crispin, A; Kneidinger, N; Leuschner, G; Meiser, B; Michel, S; Milger, K; Munker, D; Neurohr, C; Schmitzer, M; Schneider, C; Sisic, A; Veit, T; Weig, T	1
Bouros, D; Tzilas, V; Tzouvelekis, A	1
Axmann, J; Bendstrup, E; Gilberg, F; Jouneau, S; Kirchgaessler, KU; Lancaster, LH; Lederer, DJ; Maher, TM; Molina-Molina, M; Morrison, L; Noble, PW; Petzinger, U	1
Baba, T; Ikeda, S; Iwasawa, T; Katano, T; Kitamura, H; Oda, T; Ogura, T; Okuda, R; Sadoyama, S; Sekine, A; Shintani, R; Tabata, E; Takemura, T; Yamakawa, H	1
Bajwa, EK; El-Amine, M; Gorina, E; Gupta, R; Kaner, RJ; Lazarus, HM; Luckhardt, TR; Martinez, FJ; Mouded, M; Posada, K; Richeldi, L; Stauffer, J; Tutuncu, A	1
DePew, ZS; Dull, SK; Jagan, N; Malesker, MA; Moore, DR; Morrow, LE	1
Baldi, F; Macagno, F; Panico, L; Pasciuto, G; Richeldi, L	1
Dobashi, K; Hachisu, Y; Hisada, T; Izuhara, K; Kaira, K; Koga, Y; Ohta, S; Ono, J; Tsurumaki, H; Yatomi, M	1
Dempsey, TM; Limper, AH; Sangaralingham, LR; Sanghavi, D; Shah, ND; Yao, X	1
Albera, C; Behr, J; Chou, W; Costabel, U; Kirchgaessler, KU; Limb, SL; Morgenthien, E; Nathan, SD; Noble, PW; Stauffer, JL; Wuyts, WA	1
Albera, C; Gilberg, F; Glassberg, MK; Kirchgaessler, KU; Petzinger, U; Wijsenbeek, MS	1
Ancochea, J; Fernández-Fabrellas, E; Molina-Molina, M; Portal, JAR; Soriano, JB; Valenzuela, C; Xaubet, A	1
Liu, JP; Lv, XD; Pang, LJ	1
Cha, H; Cho, JM; Kim, HJ; Kim, HR; Kim, YS	1
Abe, M; Hirasawa, Y; Sakayori, M; Suzuki, K; Tatsumi, K; Terada, J; Tsushima, K; Yoshioka, K	1
Potts, J; Yogaratnam, D	1
Bonella, F; Costabel, U; Wessendorf, TE	1
Jenkins, G	1
Raghu, G; Thickett, DR	1
Cano-Jiménez, E	1
Valenzuela, C	1
Antoniou, KM; Giannarakis, I; Margaritopoulos, GA; Siafakas, NM	1
Cottin, V	4
Ancochea, J; Bollo, E; Fernández-Fabrellas, E; Franquet, T; Molina-Molina, M; Montero, MA; Serrano-Mollar, A; Xaubet, A	1
Garber, K	1
Baba, T; Hagiwara, E; Kato, T; Kitamura, H; Ogura, T; Okuda, R	1
Antoniou, KM; Margaritopoulos, GA; Siafakas, NM	1
Katayama, Y; Komada, T; Kusagawa, H; Shomura, S	1
Kanehira, Y; Tada, H; Togami, K	2
Dempsey, OJ; Miller, D	1
Kondoh, Y; Taniguchi, H	1
Homma, S; Ishida, F; Isobe, K; Itoh, T; Muramatsu, Y; Sakamoto, S; Satoh, K; Sugino, K	1
Chaudhuri, N; Duck, A; Frank, R; Holme, J; Leonard, C	1
Ancochea, J; Serrano-Mollar, A; Xaubet, A	1
Clark, P; Landells, LJ; Naidoo, B; Robertson, J	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; King, TE; Leff, JA; Nathan, SD; Noble, PW; Sahn, SA; Valeyre, D	1
Behr, J	2
Poletti, V	1
Kreuter, M	1
Akira, M; Arai, T; Hayashi, S; Inoue, Y; Kitaichi, M; Nakao, K; Okuma, T; Sasaki, Y; Sugimoto, C; Tachibana, K	1
Bendstrup, E; Costabel, U; Cottin, V; Dewint, P; Egan, JJ; Ferguson, J; Groves, R; Hellström, PM; Kreuter, M; Maher, TM; Molina-Molina, M; Nordlind, K; Sarafidis, A; Vancheri, C	1
Hunninghake, GM	1
Bradford, WZ; Castro-Bernardini, S; Fagan, EA; Glaspole, I; Glassberg, MK; Gorina, E; Hopkins, PM; Kardatzke, D; King, TE; Lancaster, L; Lederer, DJ; Nathan, SD; Noble, PW; Pereira, CA; Sahn, SA; Sussman, R; Swigris, JJ	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; King, TE; Leff, JA; Noble, PW; Sahn, SA; Valeyre, D	1
Hoffstein, V; Kardos, P; Kreuter, M	1
Kingwell, K	1
Collard, HR; Ryerson, CJ	1
Ahluwalia, N; Shea, BS; Tager, AM	1
Poletti, V; Ravaglia, C; Tomassetti, S	1
Ehlers-Tenenbaum, S; Herth, FJ; Heussel, CP; Kahn, N; Kreuter, M; Oltmanns, U; Palmowski, K; Puderbach, M; Schnabel, PA; Träger, A; Warth, A; Wenz, H; Wiebel, M	1
Kang, S	1
Covvey, JR; Mancl, EE	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Hormel, P; King, TE; Noble, PW; Sahn, SA; Valeyre, D	1
Ratner, M	1
Iwata, T; Mizobuchi, T; Nagato, K; Nakajima, T; Nakatani, Y; Ota, S; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I	1
Drakopanagiotakis, F; Günther, A; Löh, B; Markart, P; von der Beck, D	1
Crooks, MG; Hart, SP	1
Goodwin, A; Jenkins, G	1
Abe, S; Azuma, A; Bando, M; Chida, K; Fujimoto, T; Hasegawa, Y; Inoue, Y; Klüglich, M; Kondoh, Y; Mochizuki, Y; Ogura, T; Okazaki, K; Sakamoto, W; Sugiyama, Y; Tadayasu, Y; Taniguchi, H	1
Homma, S; Sakamoto, S; Sugino, K	1
Kunii, E; Moriyama, S; Niimi, A; Ohkubo, H	1
Albera, C; Bandelli, GP; Barrocu, L; Cordani, E; Drakopanagiotakis, F; Guenther, A; Loeh, B; Markart, P; Rizza, E; Seeger, W; Tello, S; von der Beck, D	1
Keating, GM; Kim, ES	1
Cavazza, A; Crestani, B; Rossi, G; Spagnolo, P; Sverzellati, N; Tzouvelekis, A; Vancheri, C	1
Spagnolo, P	2
Collard, HR; Spagnolo, P; Wells, AU	1
Bradford, WZ; Collard, HR; du Bois, RM; Ley, B; Vittinghoff, E; Weycker, D	2
Raghu, G; Selman, M	1
Kaminski, N; Rosas, IO	1
Homma, S; Ishida, F; Isobe, K; Kikuchi, N; Muramatsu, Y; Sakamoto, S; Sano, G; Satoh, K; Sugino, K; Takai, Y	1
Ahmed, D; Chaudhuri, N; Duck, A; Errhalt, P; Pigram, L	1
Cottin, V; Maher, T	1
Costabel, U	3
Corte, T; King, TE; Moodley, Y; Richeldi, L	1
Einecke, D	1
Chono, S; Kanehira, Y; Miyakoshi, K; Miyao, A; Tada, H; Togami, K	1
Chowdhury, BA; Karimi-Shah, BA	1
Aebischer, O; Benmachiche, M; Bonjour, T; Carrel, G; Castioni, J; Cosma-Rochat, M; Fournier, J; Gachoud, D; Gagliano, M; Giger, A; Greiser, J; Lamy, O; Méan, M; Mieville, A; Rouiller Larpin, N; Tusgul, S; Voruz, S; Wenger, N	1
Andreas, S; Bahmer, T; Behr, J; Claussen, M; Gläser, S; Grohé, C; Held, M; Herth, FJ; Hoeper, MM; Höffken, G; Huber, RM; Kirschner, J; Klotsche, J; Koch, A; Kohlhäufl, M; Koschel, D; Kreuter, M; Meyer, FJ; Neurohr, C; Pittrow, D; Randerath, W; Schwaiblmair, M; Skowasch, D; Welte, T; Wilkens, H; Wirtz, H	1
Bradford, WZ; Fagan, EA; Glaspole, I; Glassberg, MK; Glasscock, KF; Kardatzke, D; King, TE; Lancaster, LH; Lederer, DJ; Nathan, SD; Noble, PW; Pereira, CA; Sahn, SA; Swigris, JJ	1
Diso, D; Frati, G; Ialleni, E; Ialongo, P; Paone, G; Peruzzi, M; Quagliarini, F; Rose, D; Sebastiani, A; Venuta, F	1
Clegg, AJ; Colquitt, JL; Copley, VR; Loveman, E; O'Reilly, KM; Scott, DA	1
Maher, TM; Richeldi, L; Spagnolo, P	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Kartashov, A; King, TE; Nathan, SD; Noble, PW; Sahn, SA; Valeyre, D; Weycker, D	1
Agostini, C; Albera, C; Bandelli, GP; Bargagli, E; Biffi, A; Bocchino, M; Caminati, A; Cerri, S; Cinetto, F; Confalonieri, M; Della Porta, R; Farinelli, G; Giunta, V; Harari, S; Luppi, F; Mari, A; Pesci, A; Poletti, V; Puglisi, S; Saltini, C; Sanduzzi, A; Sebastiani, A; Specchia, C; Tirelli, F; Tomassetti, S; Vancheri, C	1
Funke, M; Geiser, T	1
Crestani, B	2
Bauer, C; Buzan, T; Colombi, D; Dinkel, J; Herth, F; Heussel, CP; Kauczor, HU; Kreuter, M; Nabers, D; Obermayer, B; Oltmanns, U; Palmowski, K; Sverzellati, N; Weinheimer, O	1
Fukunaga, A; Nishigori, C; Tsuruta, A; Washio, K	1
Butera, G; Carlucci, A; Ceriana, P; Micheletti, A; Schreiber, A	1
Danoff, SK; Lancaster, LH; Meyer, KC; Nathan, SD	1
King, CS; Nathan, SD	2
Grutters, JC; Wijsenbeek, MS; Wuyts, WA	1
Condos, R; Skaria, SD; Smaldone, GC; Yang, J	1
Hilberg, O	1
Antoniou, K; Costabel, U; Crestani, B; Egan, J; Margaritopoulos, G; Poletti, V; Wells, AU	1
Egan, J	1
Margaritopoulos, G	1
Aravena, C; Arenas, A; Labarca, G; Rada, G; Venegas, C	1
Crestani, B; Porcher, R; Richeldi, L; Thabut, G	1
Caminati, A; Harari, S	1
Behr, J; Kneidinger, N; Milger, K; Neurohr, C; Reichenberger, F	1
Azuma, A; Bando, M; Chida, K; Inoue, Y; Kakutani, S; Kudoh, S; Niimi, Y; Nukiwa, T; Ogura, T; Suga, M; Sugiyama, Y; Taniguchi, H	1
Kremer, MR; Wand, O	1
Bonella, F; Maher, TM; Spagnolo, P	1
Prasse, A	1
Elmufdi, F; Henke, CA; Kim, HJ; Perlman, DM; Tomic, R	1
Chen, BY; Dai, HP; Huang, H; Kang, J; Sun, TY; Xu, ZJ	1
George, G; Summer, R; Vaid, U	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H; Taniguchi, H	1
Azuma, A; Ebina, M; Hashimoto, S; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H; Taniguchi, H	1
Bianchini, E; Bocchino, M; Carbonelli, CM; Cerri, S; Cossarizza, A; De Biasi, S; Gibellini, L; Luppi, F; Montanari, G; Persiani, E; Richeldi, L; Sgalla, G; Vancheri, C; Zamparelli, AS; Zucchi, L	1
Belloli, EA; Flaherty, KR; Martinez, FJ	1
Noble, PW; Selvaggio, AS	1
Arita, M; Fukuda, Y; Hashimoto, T; Ishida, T; Ito, A; Ito, I; Iwasaku, M; Konishi, S; Kourogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Tachibana, H; Takaiwa, T; Tanaka, M; Tokioka, F; Tsubouchi, K; Watanabe, N; Yoshioka, H	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Fagan, EA; Fishman, RS; Glaspole, I; Glassberg, MK; King, TE; Lancaster, L; Lederer, DJ; Leff, JA; Nathan, SD; Noble, PW; Pereira, CA; Swigris, JJ; Valeyre, D	1
Munakata, M	1
Locy, ML; Luckhardt, TR; Rangarajan, S; Thannickal, VJ	1
Ripamonti, E; Russell, AM; Vancheri, C	1
Bonella, F; Kreuter, M; Maher, TM; Spagnolo, P; Wijsenbeek, M	1
Morrow, TJ	1
Fraser, E; Hoyles, RK	1
Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G	1
Beyene, J; Brozek, J; Garcia, CC; Neupane, B; Raghu, G; Richeldi, L; Rochwerg, B; Schünemann, H; Zhang, Y	1
Kaarteenaho, R; Karvonen, H; Korpela, S; Lappi-Blanco, E; Lehtonen, ST; Sköld, MC; Sormunen, R; Veijola, A; Zagai, U	1
Funke-Chambour, M; Geiser, T	1
Azuma, A; Bando, M; Homma, S; Ogura, T; Sugiyama, Y; Taniguchi, H; Watanabe, K; Yamauchi, H	1
Fukuda, Y; Goto, H; Hanibuchi, M; Morizumi, S; Nishioka, Y; Sato, S; Takahashi, M; Toyoda, Y	1
Baba, T; Ikeda, S; Kitamura, H; Morita, M; Ogura, T; Sekine, A; Yamakawa, H	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Fagan, EA; Fishman, RS; Glaspole, I; Glassberg, MK; Glasscock, KF; King, TE; Lancaster, L; Lederer, DJ; Lin, Z; Nathan, SD; Noble, PW; Pereira, CA; Swigris, JJ; Valeyre, D; Wells, AU	1
Hanada, S; Kishi, K; Kurosaki, A; Miyamoto, A; Mochizuki, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Takeyasu, M; Uruga, H	1
Costabel, U; Herth, FJ; Kirchgaessler, KU; Kolb, M; Koschel, D; Kreuter, M; Maher, TM; Renzoni, E; Spagnolo, P; Weycker, D; Wuyts, W	1
Beltramo, G; Borie, R; Crestani, B; Justet, A; Manali, ED; Pradère, P; Spagnolo, P	1
Hagmeyer, L; Priegnitz, C; Randerath, WJ; Treml, M	1
Corte, TJ; Jo, HE; Moodley, Y; Randhawa, S	1
Bacon, KB; Boehme, SA; DiTirro, DN; Franz-Bacon, K; Ly, TW	1
Albera, C; Beck, J; Behr, J; Bendstrup, E; Crestani, B; Günther, A; Koschel, D; Kreuter, M; Lin, CY; Olschewski, H; Sköld, CM; Wallaert, B; Wells, A; Wuyts, W	1
Anderson, A; Nathan, SD; Shifren, A	1
Bondue, B; Corhay, JL; Guiot, J; Henket, M; Louis, R	1
Matěj, R; Vašáková, M	1
Jones, MG; Richeldi, L	1
Balìa, C; Celi, A; Faìta, F; Lombardi, S; Neri, T; Paggiaro, P; Pedrinelli, R; Petrini, S; Scalise, V	1
Adams, TN; Battaile, JT; Eiswirth, C; Newton, CA	1
Brown, KK	1
Calandriello, L; Dubini, A; Farchione, A; Franchi, P; Larici, AR; Mastrobattista, A; Poletti, V; Tagliaboschi, L; Tomassetti, S; Varone, F; Viglietta, L	1
Gomez, DC; Mehrad, B	1
Asato, Y; Azuma, A; Chida, M; Fukuoka, J; Hiroshima, K; Ikeda, N; Iwasawa, T; Iwata, T; Katakami, N; Kuwano, K; Matsuura, M; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Okada, M; Okami, J; Okubo, K; Sakai, S; Sakamoto, K; Tada, H; Takenoyama, M; Tomii, K; Tsuboi, M; Yamashita, M; Yamashita, Y; Yokouchi, H; Yoshida, S; Yoshimura, K; Yoshino, I	1
Albera, C; Costabel, U; Fagan, EA; Glassberg, MK; Gorina, E; Lancaster, L; Lederer, DJ; Nathan, SD; Spirig, D; Swigris, JJ	1
Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Rogliani, P	1
Chilvers, ER; Fiddler, CA; Miremadi, A; Parfrey, H; Simler, N	1
Adegunsoye, A; Strek, ME	1
Fletcher, S; Jones, MG; Limbrey, R; Marshall, BG; Richeldi, L; Sgalla, G; Spinks, K	1
Fujiwara, T; Iwata, T; Nakajima, T; Suzuki, H; Wada, H; Yoshida, S; Yoshino, I	1
Abel, PW; Casale, TB; Jiang, H; Mehrotra, S; Panettieri, RA; Rennard, S; Toews, ML; Tu, Y; Wolff, DW; Xie, Y; Zhang, Q	1
Bando, M	1
Robinson, HC	1
Clarke, DL; Crestani, B; Murray, LA; Sleeman, MA	1
Bonella, F; Costabel, U; Kirchgaessler, KU; Kolb, M; Kreuter, M; Maher, TM; Spagnolo, P; Weycker, D	1
Biju, G; Jyothi, E; Kumar, NK; Narayan, KV; Suraj, KP	1
Hosein, K; Le, J; Mura, M	1
Altraja, A; Bendstrup, E; Ferrara, G; Gudmundsson, G; Hilberg, O; Kaarteenaho, R; Myllärniemi, M; Sjåheim, T; Sköld, CM	1
Delanote, I; Verbeken, EK; Verleden, GM; Vos, R; Wuyts, WA; Yserbyt, J	1
Albera, C; Bradford, WZ; Costabel, U; Daigl, M; Glaspole, I; Glassberg, MK; Kardatzke, DR; Kirchgaessler, KU; Lancaster, LH; Lederer, DJ; Nathan, SD; Noble, PW; Pereira, CA; Swigris, JJ; Valeyre, D	1
Guo, F; Song, X; Yu, W	1
Bayly, S; Brown, KK; Chien, JW; Collard, HR; Cottin, V; Gibson, KF; Gong, Q; Kaner, RJ; Lederer, DJ; Martinez, FJ; Moreau, E; Noble, PW; O'Riordan, TG; Patterson, SD; Raghu, G; Smith, V; Song, JW; Wells, AU; Whelan, TP; Wuyts, W; Zhang, JJ	1
Akasaki, T; Hamada, M; Hara, M; Ise, S; Ishimoto, H; Ishizu, M; Izumi, M; Kawabata, M; Kawasaki, M; Koreeda, Y; Kumazoe, H; Maki, S; Mukae, H; Nagata, N; Oda, K; Takakura, K; Takata, S; Wakamatsu, K; Yoshimi, M	1
Chang, S; Diamantopoulos, A; Esser, D; LeReun, C; Maher, TM; Rinciog, C; Watkins, M	1
Jeldres, A; Labarca, G	1
Antony, VB; Bae, S; de Andrade, J; Li, FJ; Li, H; Liu, G; Liu, RM; Luckhardt, T; Rangarajan, S; Surolia, R; Thannickal, VJ; Wang, Z; Zhou, Y	1
Didiasova, M; Kwapiszewska, G; Lauth, M; Markart, P; Schaefer, L; Seeger, W; Singh, R; Wilhelm, J; Wujak, L; Wygrecka, M; Zakrzewicz, D	1
Aichler, M; Bächinger, HP; Behr, J; Eickelberg, O; Hatz, R; Heinzelmann, K; Ishikawa, Y; Knüppel, L; Staab-Weijnitz, CA; Walch, A	1
Aiello, M; Bertorelli, G; Bocchino, M; Chetta, A; Fiore-Donati, A; Fois, A; Marinari, S; Oggionni, T; Polla, B; Rosi, E; Sanduzzi, A; Stanziola, A; Varone, F	1
Kim, BS; Kim, GW; Kim, HS; Kim, JM; Kim, MB; Ko, HC; Park, MY; Shim, WH	1
George, PM; Wells, AU	1
Collard, HR	2
Daigl, M; Edwards, SC; Fisher, M; Fleetwood, K; Glanville, J; Gsteiger, S; McCool, R	1
Dejonckheere, F; Fisher, M; Hill, C; Maher, TM; Marshall, J; Nathan, SD; Thuresson, PO	1
Dejonckheere, F; Maher, TM; Nathan, SD	1
Acosta, O; Ancochea, J; Bollo, E; Castillo, D; Fernández-Fabrellas, E; Molina-Molina, M; Rodríguez-Portal, JA; Valenzuela, C; Xaubet, A	1
Hasegawa, T; Tango, T	1
Wang, ZL	1
Oku, H; Tokura, T; Tsukamoto, Y	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Raghu, G; Sato, A; Suga, M; Taguchi, Y; Takahashi, H; Takeuchi, M; Taniguchi, H	1
Azuma, A	2
Fairclough, D; Swigris, J	1
Bouros, D	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Glassberg, MK; Kardatzke, D; King, TE; Lancaster, L; Noble, PW; Sahn, SA; Szwarcberg, J; Valeyre, D	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Sato, A; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H; Taniguchi, H	1
Kirkpatrick, P; Richeldi, L; Yasothan, U	1
du Bois, RM; Richeldi, L	1
Carter, NJ	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Sato, A; Suga, M; Taguchi, Y; Takahashi, H; Taniguchi, H	1
Baba, T; Gotoh, T; Inoue, T; Iwasawa, T; Kanauchi, T; Komagata, T; Morita, S; Ogura, T; Sakai, F; Yazawa, T	1
Günther, A; Korfei, M; Mahavadi, P; Markart, P; Ruppert, C; von der Beck, D	1
Richeldi, L	2
Bendstrup, E; du Bois, R; Hilberg, O; Simonsen, U	1
Cerri, S; Luppi, F; Richeldi, L; Spagnolo, P	1
Kagouridis, K; Kolilekas, L; Manali, ED; Papiris, SA; Triantafillidou, C; Tsangaris, I	1
Adamali, HI; Maher, TM	1
Behr, J; Hoeper, MM; Klotsche, J; Kreuter, M; Pittrow, D; Wirtz, H	1

Reviews

132 review(s) available for pirfenidone and Cryptogenic Fibrosing Alveolitis

Article	Year
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. Journal of medicinal chemistry, 2017, 01-26, Volume: 60, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antioxidants; Apoptosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; NADPH Oxidase 1; NADPH Oxidase 4; NADPH Oxidases; Patents as Topic; Protein Kinase Inhibitors; Pyridones; Receptors, Lysophosphatidic Acid	2017
Pirfenidone as a novel cardiac protective treatment. Heart failure reviews, 2022, Volume: 27, Issue:2 Topics: Animals; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Myocytes, Cardiac; Pyridones	2022
The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. European journal of medical research, 2021, Oct-30, Volume: 26, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Exanthema; Humans; Idiopathic Pulmonary Fibrosis; Lung; Nausea; Progression-Free Survival; Pyridones; Treatment Outcome; Vital Capacity	2021
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC pulmonary medicine, 2021, Dec-11, Volume: 21, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Cause of Death; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Fibrosis; Pyridones; Treatment Outcome	2021
Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials. BMJ open, 2021, 12-31, Volume: 11, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Progression-Free Survival; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity	2021
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. International journal of molecular sciences, 2023, Apr-25, Volume: 24, Issue:9 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Pyridones; Treatment Outcome	2023
Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. BMC pulmonary medicine, 2023, Nov-29, Volume: 23, Issue:1 Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome	2023
Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape. The American journal of managed care, 2019, Volume: 25, Issue:11 Suppl Topics: Age Distribution; Aging; Antineoplastic Agents; Chronic Disease; Comorbidity; Disease Progression; Health Expenditures; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Sex Distribution	2019
The therapy of idiopathic pulmonary fibrosis: what is next? European respiratory review : an official journal of the European Respiratory Society, 2019, Sep-30, Volume: 28, Issue:153 Topics: Animals; Comorbidity; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Molecular Targeted Therapy; Palliative Care; Pyridones; Respiratory System Agents; Respiratory Therapy; Risk Factors; Treatment Outcome	2019
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory research, 2019, Sep-06, Volume: 20, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones; Time-to-Treatment	2019
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. Expert review of respiratory medicine, 2019, Volume: 13, Issue:12 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones; Treatment Outcome	2019
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2019, Sep-30, Volume: 28, Issue:153 Topics: Animals; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Diseases, Interstitial; Pyridones; Treatment Outcome; Vital Capacity	2019
Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions. Nutrients, 2020, Apr-17, Volume: 12, Issue:4 Topics: Behavior; Cardiovascular Diseases; Comorbidity; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Muscle Strength; Nutrition Assessment; Nutrition Disorders; Nutritional Physiological Phenomena; Nutritional Status; Patient Education as Topic; Pyridones	2020
Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC pulmonary medicine, 2020, May-07, Volume: 20, Issue:1 Topics: Acetylcysteine; Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity	2020
Evolution and treatment of idiopathic pulmonary fibrosis. Presse medicale (Paris, France : 1983), 2020, Volume: 49, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Connective Tissue Growth Factor; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Integrins; Leukotriene Antagonists; Lung Transplantation; Microbiota; Middle Aged; Multimorbidity; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Kinase Inhibitors; Pyridones; Serum Amyloid P-Component	2020
Lung transplantation for idiopathic pulmonary fibrosis. Presse medicale (Paris, France : 1983), 2020, Volume: 49, Issue:2 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Comorbidity; Disease Progression; Frailty; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Lung Transplantation; Prognosis; Pyridones; Telomere Shortening	2020
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:8 Topics: Animals; Antibodies, Monoclonal, Humanized; Connective Tissue Growth Factor; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2020
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respiratory investigation, 2020, Volume: 58, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers; Disease Progression; Female; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Middle Aged; Prognosis; Pyridones; Telomere	2020
Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Development; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones	2020
[Antifibrotic therapy and progressive lung fibrosis]. Revue medicale suisse, 2020, Jun-17, Volume: 16, Issue:698 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pulmonary Fibrosis; Pyridones	2020
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease. Lung, 2020, Volume: 198, Issue:4 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Vital Capacity	2020
Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Dyspnea; Fatigue; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mental Health; Protein Kinase Inhibitors; Pyridones; Quality of Life	2020
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:2 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic	2021
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis. The Annals of pharmacotherapy, 2021, Volume: 55, Issue:6 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2021
Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature. The journal of medical investigation : JMI, 2020, Volume: 67, Issue:3.4 Topics: Humans; Hypoxia; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed	2020
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Expert opinion on drug safety, 2021, Volume: 20, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Education as Topic; Protein Kinase Inhibitors; Pyridones; Randomized Controlled Trials as Topic	2021
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. Expert opinion on emerging drugs, 2021, Volume: 26, Issue:2 Topics: Animals; Clinical Trials, Phase II as Topic; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones; Randomized Controlled Trials as Topic	2021
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest, 2021, Volume: 160, Issue:5 Topics: Antifibrotic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Mortality; Pyridones; Symptom Flare Up; Treatment Outcome	2021
Clinical trial research in focus: why do so many clinical trials fail in IPF? The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Research Design; Treatment Failure	2017
Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration; international review of thoracic diseases, 2017, Volume: 93, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Enzyme Inhibitors; Genotype; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Phenotype; Precision Medicine; Pyridones	2017
Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis. Southern medical journal, 2017, Volume: 110, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Fibrinolytic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein-Tyrosine Kinases; Pyridones	2017
Model-based Meta-Analysis on the Efficacy of Pharmacological Treatments for Idiopathic Pulmonary Fibrosis. CPT: pharmacometrics & systems pharmacology, 2017, Volume: 6, Issue:10 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Models, Statistical; Pyridones; Regression Analysis; Treatment Outcome; Vital Capacity	2017
Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory medicine, 2017, Volume: 129 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Middle Aged; Palliative Care; Patient Education as Topic; Practice Guidelines as Topic; Prevalence; Pyridones; Quality of Life; Young Adult	2017
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient? Drugs & aging, 2017, Volume: 34, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Decision Making; Disease Management; Drug-Related Side Effects and Adverse Reactions; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Vital Capacity	2017
Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. Saudi medical journal, 2017, Volume: 38, Issue:9 Topics: Humans; Idiopathic Pulmonary Fibrosis; Meta-Analysis as Topic; Placebos; Pyridones; Randomized Controlled Trials as Topic; Respiratory Function Tests	2017
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Approval; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory medicine, 2017, Volume: 131 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2017
Severe idiopathic pulmonary fibrosis: what can be done? European respiratory review : an official journal of the European Respiratory Society, 2017, Sep-30, Volume: 26, Issue:145 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Palliative Care; Pyridones; Respiratory Function Tests; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome	2017
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. European respiratory review : an official journal of the European Respiratory Society, 2017, Sep-30, Volume: 26, Issue:145 Topics: Animals; Diffusion of Innovation; Disease Progression; Drug Discovery; Drugs, Investigational; Forecasting; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Remission Induction; Respiratory System Agents; Severity of Illness Index; Treatment Outcome	2017
Nintedanib for Idiopathic Pulmonary Fibrosis. Journal of pharmacy practice, 2019, Volume: 32, Issue:2 Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones	2019
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. The European respiratory journal, 2017, Volume: 50, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2017, Dec-31, Volume: 26, Issue:146 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Humans; Idiopathic Pulmonary Fibrosis; Lung; Medication Adherence; Pyridones; Recovery of Function; Risk Factors; Time Factors; Treatment Outcome	2017
Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory research, 2018, 02-22, Volume: 19, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Tomography, X-Ray Computed	2018
[Nintedanib in the treatment of fibrosing interstital lung diseases]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2018, Mar-27, Volume: 44, Issue:261 Topics: Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridones; Treatment Outcome	2018
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert opinion on emerging drugs, 2018, Volume: 23, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Design; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2018
Idiopathic Pulmonary Fibrosis. The New England journal of medicine, 2018, May-10, Volume: 378, Issue:19 Topics: Diagnosis, Differential; Dyspnea; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Oxygen Inhalation Therapy; Prognosis; Pyridones; Risk Factors; Tomography, X-Ray Computed; Transforming Growth Factor beta	2018
Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respiratory investigation, 2018, Volume: 56, Issue:4 Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Glycine; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Japan; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic; Prognosis; Pyridones; Quality of Health Care; Sulfonamides; Survival Rate	2018
Use of animal models in IPF research. Pulmonary pharmacology & therapeutics, 2018, Volume: 51 Topics: Animals; Bleomycin; Disease Models, Animal; Drug Development; Drug Evaluation, Preclinical; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory Function Tests	2018
Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies. Archives of pathology & laboratory medicine, 2018, Volume: 142, Issue:9 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2018
Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2019, Volume: 37, Issue:6 Topics: Cost-Benefit Analysis; Humans; Idiopathic Pulmonary Fibrosis; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Referral and Consultation	2019
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annual review of medicine, 2019, 01-27, Volume: 70 Topics: Aged; Biopsy, Needle; Chronic Disease; Comprehension; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Indoles; Lung Transplantation; Male; Middle Aged; Precision Medicine; Prognosis; Pyridones; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Treatment Outcome	2019
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. International journal of molecular sciences, 2019, Jan-30, Volume: 20, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Myofibroblasts; Pyridones	2019
Inflammation and immunity in IPF pathogenesis and treatment. Respiratory medicine, 2019, Volume: 147 Topics: Adaptive Immunity; Anti-Inflammatory Agents; Clinical Trials as Topic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Immunity, Innate; Indoles; Inflammation; Protein Kinase Inhibitors; Pyridones	2019
Evaluation and management of Idiopathic Pulmonary Fibrosis. Respiratory investigation, 2019, Volume: 57, Issue:4 Topics: Biomarkers; Chronic Disease; Cough; Diagnosis, Differential; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; L-Lactate Dehydrogenase; Mucin-1; Pyridones; Respiratory Function Tests; Tomography, X-Ray Computed; Vital Capacity	2019
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options. Drugs & aging, 2019, Volume: 36, Issue:6 Topics: Aging; Drug Development; Extracellular Matrix; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic	2019
Current and Future Idiopathic Pulmonary Fibrosis Therapy. The American journal of the medical sciences, 2019, Volume: 357, Issue:5 Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2019
Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2013
[Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:11 Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Evidence-Based Medicine; Female; Germany; Humans; Idiopathic Pulmonary Fibrosis; Male; Prevalence; Pyridones; Treatment Outcome	2013
An update on idiopathic pulmonary fibrosis. Panminerva medica, 2013, Volume: 55, Issue:2 Topics: Animals; Early Diagnosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Predictive Value of Tests; Prognosis; Pyridones; Risk Factors	2013
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respiratory research, 2013, Volume: 14 Suppl 1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Prevalence; Pyridones; Risk Factors; Survival Rate; Treatment Outcome	2013
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. European respiratory review : an official journal of the European Respiratory Society, 2013, Sep-01, Volume: 22, Issue:129 Topics: Animals; History, 20th Century; History, 21st Century; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Respiratory System Agents; Treatment Outcome	2013
Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Humans; Idiopathic Pulmonary Fibrosis; Prognosis; Pyridones; Risk Assessment; Severity of Illness Index; Survival Rate; Vital Capacity	2014
The diagnosis and treatment of idiopathic pulmonary fibrosis. Deutsches Arzteblatt international, 2013, Dec-23, Volume: 110, Issue:51-52 Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Prevalence; Pyridones; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2013
Pirfenidone: an update on clinical trial data and insights from everyday practice. European respiratory review : an official journal of the European Respiratory Society, 2014, Mar-01, Volume: 23, Issue:131 Topics: Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Randomized Controlled Trials as Topic; Respiratory System Agents; Time Factors; Treatment Outcome	2014
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Advances in therapy, 2014, Volume: 31, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Tumor Necrosis Factor-alpha	2014
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.), 2014, Volume: 19, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Aminotransferases; Biomarkers; Dose-Response Relationship, Drug; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Randomized Controlled Trials as Topic; Time Factors	2014
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. American journal of respiratory and critical care medicine, 2014, Oct-15, Volume: 190, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Pyridones; Wound Healing	2014
Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert review of respiratory medicine, 2014, Volume: 8, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Quality of Life; Respiratory Function Tests; Treatment Outcome	2014
Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:12 Topics: Acetylcysteine; Anti-Inflammatory Agents; Azathioprine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prednisone; Pyridones; Randomized Controlled Trials as Topic	2014
[Idiopathic pulmonary fibrosis]. La Revue du praticien, 2014, Volume: 64, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2014
[Antifibrotic treatment]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:49 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cystine; Drug Approval; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Vital Capacity	2014
Two new drugs for idiopathic pulmonary fibrosis. The Medical letter on drugs and therapeutics, 2014, Volume: 56, Issue:1457 Topics: Drug Approval; Drugs, Investigational; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Tumor Necrosis Factor-alpha; United States	2014
Novel approaches to pulmonary fibrosis. Clinical medicine (London, England), 2014, Volume: 14 Suppl 6 Topics: Biomarkers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2014
Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respiratory investigation, 2015, Volume: 53, Issue:1 Topics: Acetylcysteine; Empirical Research; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Japan; Oximetry; Patient Selection; Pyridones; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Vital Capacity	2015
Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs, 2015, Volume: 75, Issue:2 Topics: Administration, Oral; Animals; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2015
Idiopathic pulmonary fibrosis: an update. Annals of medicine, 2015, Volume: 47, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Middle Aged; Pyridones; Risk Factors	2015
Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug discovery today, 2015, Volume: 20, Issue:5 Topics: Animals; Comorbidity; Disease Models, Animal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Risk Factors; Time Factors; Treatment Outcome	2015
IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Advances in therapy, 2015, Volume: 32, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Europe; Humans; Idiopathic Pulmonary Fibrosis; Middle Aged; Nurses; Patient Education as Topic; Pyridones; Quality of Life; Surveys and Questionnaires; Treatment Outcome; United Kingdom	2015
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2015, Volume: 24, Issue:135 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Registries	2015
The changing treatment landscape in idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2015, Volume: 24, Issue:135 Topics: Anti-Inflammatory Agents, Non-Steroidal; Europe; Humans; Idiopathic Pulmonary Fibrosis; Practice Guidelines as Topic; Pyridones; United States	2015
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Respirology (Carlton, Vic.), 2015, Volume: 20, Issue:3 Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Treatment Outcome; Tumor Necrosis Factor-alpha	2015
Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis. BMC pulmonary medicine, 2015, Apr-18, Volume: 15 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2015
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. Pharmacology & therapeutics, 2015, Volume: 152 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic	2015
Idiopathic pulmonary fibrosis: the turning point is now! Swiss medical weekly, 2015, Volume: 145 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Disease Progression; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones	2015
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions. Chest, 2015, Volume: 148, Issue:1 Topics: Age Factors; Aged; Antineoplastic Agents; Disease Management; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient-Centered Care; Precision Medicine; Prognosis; Pyridones	2015
Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Current opinion in pulmonary medicine, 2015, Volume: 21, Issue:5 Topics: Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2015
Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Aug-03, Volume: 32 Suppl 1 Topics: Aged; Biopsy, Needle; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Male; Middle Aged; Needs Assessment; Practice Guidelines as Topic; Prognosis; Pyridones; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Survival Analysis; Tomography, X-Ray Computed	2015
Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. PloS one, 2015, Volume: 10, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2015
Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. European respiratory review : an official journal of the European Respiratory Society, 2015, Volume: 24, Issue:137 Topics: Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome	2015
[Novel therapies for idiopathic pulmonary fibrosis]. Harefuah, 2015, Volume: 154, Issue:7 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory Mucosa; Survival Rate	2015
Novel mechanisms and treatment of idiopathic pulmonary fibrosis. Discovery medicine, 2015, Volume: 20, Issue:109 Topics: Clinical Trials as Topic; Disease Progression; Environmental Exposure; Fibroblasts; Gastroesophageal Reflux; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mutation; Myofibroblasts; Polymorphism, Genetic; Prognosis; Pyridones; Treatment Outcome	2015
Update in Interstitial Lung Disease 2014. American journal of respiratory and critical care medicine, 2015, Sep-01, Volume: 192, Issue:5 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Doxycycline; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis, Pulmonary; Sirolimus; Smoking; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha	2015
Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis. Annual review of medicine, 2016, Volume: 67 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Disease-Free Survival; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2016
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. The European respiratory journal, 2016, Volume: 47, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Exercise Test; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; International Cooperation; Male; Middle Aged; Pulmonary Diffusing Capacity; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity	2016
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? Drugs, 2016, Volume: 76, Issue:3 Topics: Aging; Clinical Trials, Phase II as Topic; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones	2016
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed research international, 2015, Volume: 2015 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2015
Therapeutic advances in idiopathic pulmonary fibrosis. Clinical medicine (London, England), 2016, Volume: 16, Issue:1 Topics: Anti-Inflammatory Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2016
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Chest, 2016, Volume: 149, Issue:3 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin	2016
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC medicine, 2016, Feb-03, Volume: 14 Topics: Acetylcysteine; Adult; Anticoagulants; Bayes Theorem; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Male; Middle Aged; Pyridones; Quality of Life; Treatment Outcome; Young Adult	2016
[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis]. Therapeutische Umschau. Revue therapeutique, 2016, Volume: 73, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Kidney Diseases; Pyridones; Respiratory System Agents; Treatment Outcome	2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:5 Topics: Aged; Antacids; Clinical Trials, Phase III as Topic; Disease Progression; Exercise Tolerance; Female; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung; Male; Middle Aged; Patient Admission; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity; Walk Test	2016
Pharmacological management of IPF. Respirology (Carlton, Vic.), 2016, Volume: 21, Issue:4 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunomodulation; Immunosuppressive Agents; Indoles; Male; Middle Aged; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2016
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert opinion on drug safety, 2016, Volume: 15, Issue:7 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Medication Adherence; Patient Education as Topic; Pyridones; Randomized Controlled Trials as Topic	2016
Recent Advances and Future Needs in Interstitial Lung Diseases. Seminars in respiratory and critical care medicine, 2016, Volume: 37, Issue:3 Topics: Clinical Trials as Topic; Forecasting; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Pyridones; Quality of Life	2016
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulmonary pharmacology & therapeutics, 2016, Volume: 40 Topics: Acetylcysteine; Anti-Inflammatory Agents; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, Volume: 150, Issue:6 Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Prognosis; Pyridones	2016
The safety of new drug treatments for idiopathic pulmonary fibrosis. Expert opinion on drug safety, 2016, Volume: 15, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2016
Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis. Respiratory investigation, 2016, Volume: 54, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2016
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? Pharmacology & therapeutics, 2017, Volume: 169 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Precision Medicine; Prognosis; Pyridones	2017
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of internal medicine, 2017, Volume: 281, Issue:2 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2017
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Clinical Trials, Phase III as Topic; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity	2017
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics, 2017, Volume: 35, Issue:4 Topics: Acetylcysteine; Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Markov Chains; Models, Economic; Pyridones; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom	2017
Is pirfenidone effective for idiopathic pulmonary fibrosis? Medwave, 2017, Jan-17, Volume: 17, Issue:Suppl1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic	2017
The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulmonary pharmacology & therapeutics, 2017, Volume: 44 Topics: Disease Progression; Early Diagnosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Patient Care Team; Patient-Centered Care; Prognosis; Protein Kinase Inhibitors; Pyridones	2017
Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Endpoint Determination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:3-b Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:3-b Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Phosphodiesterase 5 Inhibitors; Pyridones; Survival Rate	2017
Advances in understanding of idiopathic pulmonary fibrosis. Chinese medical journal, 2009, Apr-05, Volume: 122, Issue:7 Topics: Adrenal Cortex Hormones; Animals; Anticoagulants; Antioxidants; Humans; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Lung Transplantation; Pyridones	2009
Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert review of respiratory medicine, 2010, Volume: 4, Issue:3 Topics: Animals; Clinical Trials as Topic; Disease Progression; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Recovery of Function; Respiratory System Agents; Severity of Illness Index; Time Factors; Treatment Outcome	2010
Pirfenidone in idiopathic pulmonary fibrosis. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Models, Animal; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Research Design; Treatment Outcome	2010
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert review of respiratory medicine, 2011, Volume: 5, Issue:4 Topics: Australia; Double-Blind Method; Europe; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mexico; North America; Pyridones; Respiratory System Agents; Time Factors; Treatment Outcome; Vital Capacity	2011
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? European respiratory review : an official journal of the European Respiratory Society, 2011, Sep-01, Volume: 20, Issue:121 Topics: Animals; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Respiratory System Agents; Treatment Outcome	2011
Pirfenidone: in idiopathic pulmonary fibrosis. Drugs, 2011, Sep-10, Volume: 71, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome	2011
Pirfenidone treatment of idiopathic pulmonary fibrosis. Therapeutic advances in respiratory disease, 2012, Volume: 6, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Vital Capacity	2012
[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:12 Topics: Acetylcysteine; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antioxidants; Biopsy; Expectorants; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridones; Tomography, X-Ray Computed	2012
Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2012, Jun-01, Volume: 21, Issue:124 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enzyme Inhibitors; Epithelial Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Alveoli; Pyridones	2012
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2012, Jun-01, Volume: 21, Issue:124 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease-Free Survival; Humans; Idiopathic Pulmonary Fibrosis; Interferon-gamma; Pyridones; Recombinant Proteins; Treatment Outcome	2012
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. European respiratory review : an official journal of the European Respiratory Society, 2012, Jun-01, Volume: 21, Issue:124 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Prognosis; Pyridones; Survival Rate; Treatment Outcome; Vital Capacity	2012
Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. The clinical respiratory journal, 2012, Volume: 6, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2012
The big clinical trials in idiopathic pulmonary fibrosis. Current opinion in pulmonary medicine, 2012, Volume: 18, Issue:5 Topics: Bosentan; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome	2012
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug design, development and therapy, 2012, Volume: 6 Topics: Acetylcysteine; Amino Acid Oxidoreductases; Animals; Antiviral Agents; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-13; Lung Transplantation; MicroRNAs; Protein Kinase Inhibitors; Pyridones; Transforming Growth Factor beta	2012
[Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:49 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cross-Cultural Comparison; Cross-Sectional Studies; Female; Germany; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Prognosis; Prospective Studies; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Rare Diseases; Registries; Sex Factors; Survival Analysis; Treatment Outcome	2012

Trials

49 trial(s) available for pirfenidone and Cryptogenic Fibrosing Alveolitis

Article	Year
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Scientific reports, 2021, 09-08, Volume: 11, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Propensity Score; Pyridones; Sildenafil Citrate; Treatment Outcome; Vital Capacity	2021
Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. Medicine, 2022, Jun-03, Volume: 101, Issue:22 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Vital Capacity	2022
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax, 2023, Volume: 78, Issue:9 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity	2023
Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax, 2023, Volume: 78, Issue:11 Topics: Adult; Alveolitis, Extrinsic Allergic; COVID-19; Disease Progression; Double-Blind Method; Humans; Idiopathic Pulmonary Fibrosis; Pandemics; Pyridones; Treatment Outcome; Vital Capacity	2023
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. Advances in therapy, 2023, Volume: 40, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2023
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy. Respiratory medicine, 2023, Volume: 217 Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones	2023
Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial. The European respiratory journal, 2023, Volume: 62, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diet; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2023
Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Advances in therapy, 2019, Volume: 36, Issue:10 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Disease; Female; Hemorrhage; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Risk Factors; Treatment Outcome; Warfarin	2019
Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respiratory research, 2019, Oct-24, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Luxembourg; Male; Middle Aged; Mortality; Pyridones; Registries; Respiratory Function Tests; Treatment Outcome	2019
An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Archivos de bronconeumologia, 2020, Volume: 56, Issue:3 Topics: Adult; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Carbon Monoxide; Double-Blind Method; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Lung; Male; Middle Aged; Prednisone; Prospective Studies; Pyridones; Quality of Life; Treatment Outcome; Vital Capacity	2020
Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. American journal of respiratory and critical care medicine, 2020, 08-01, Volume: 202, Issue:3 Topics: Aged; Aged, 80 and over; Anxiety; Depression; Disease Management; Female; Home Care Services; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Netherlands; Patient Reported Outcome Measures; Pyridones; Quality of Life; Spirometry; Telemedicine; Vital Capacity	2020
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respiratory research, 2020, Jul-23, Volume: 21, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Motivation; Patient Satisfaction; Prospective Studies; Pyridones; Self Report; Surveys and Questionnaires; Treatment Outcome	2020
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. The European respiratory journal, 2021, Volume: 57, Issue:1 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Japan; Pyridones; Treatment Outcome; Vital Capacity	2021
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet. Respiratory medicine, 2021, Volume: 9, Issue:1 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Sildenafil Citrate	2021
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respiratory research, 2020, Nov-30, Volume: 21, Issue:1 Topics: Aged; Biomarkers; Body Mass Index; Double-Blind Method; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pulmonary Surfactant-Associated Protein D; Pyridones; Time Factors; Treatment Outcome; Vital Capacity	2020
The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial. Chest, 2021, Volume: 160, Issue:4 Topics: Aged; Anti-Bacterial Agents; Antifibrotic Agents; Antitussive Agents; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Polypharmacy; Pyridones; Treatment Outcome	2021
A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers. Advances in therapy, 2017, Volume: 34, Issue:9 Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Capsules; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Tablets; Therapeutic Equivalency; Young Adult	2017
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American journal of respiratory and critical care medicine, 2018, 02-01, Volume: 197, Issue:3 Topics: Aged; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Safety; Pyridones; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome	2018
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration; international review of thoracic diseases, 2017, Volume: 94, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2017
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. Respiratory medicine, 2018, Volume: 138 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Multicenter Studies as Topic; Pyridones; Randomized Controlled Trials as Topic; Research Design; Sildenafil Citrate; Vasodilator Agents	2018
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. The European respiratory journal, 2018, Volume: 52, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Internationality; Lung; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity	2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, Volume: 155, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Disease Progression; Dose-Response Relationship, Drug; Europe; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Survival Rate; Treatment Outcome; United States; Vital Capacity	2019
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. The European respiratory journal, 2019, Volume: 53, Issue:3 Topics: Acetates; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Safety; Pyridones; Treatment Outcome	2019
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory research, 2019, Mar-12, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome	2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, Volume: 16, Issue:7 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Prognosis; Pyridones; Risk Assessment; Severity of Illness Index; Survival Rate; Time-to-Treatment; Treatment Outcome; Vital Capacity	2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory medicine, 2019, Volume: 153 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Studies; Dyspnea; Exercise Tolerance; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mortality; Placebos; Pulmonary Diffusing Capacity; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity	2019
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. The European respiratory journal, 2019, Volume: 54, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Quality of Life; Severity of Illness Index; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity	2019
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England journal of medicine, 2014, May-29, Volume: 370, Issue:22 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity	2014
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014, Oct-20, Volume: 31, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Australia; Disease Progression; Europe; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; North America; Prospective Studies; Pulmonary Diffusing Capacity; Pyridones; Time Factors; Treatment Outcome; Vital Capacity	2014
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. The European respiratory journal, 2015, Volume: 45, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Middle Aged; Patient Safety; Pyridones; Treatment Outcome; Vital Capacity	2015
Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. The European respiratory journal, 2015, Volume: 45, Issue:5 Topics: Age Factors; Aged; Algorithms; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Interferon-gamma; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Predictive Value of Tests; Prognosis; Pyridones; Recombinant Proteins; Risk Assessment; Sex Factors; Statistics as Topic	2015
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest, 2015, Volume: 148, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Vital Capacity	2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respiratory medicine, 2015, Volume: 109, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Exercise Test; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Prognosis; Pyridones; Quality of Life; Surveys and Questionnaires; Time Factors; Tumor Necrosis Factor-alpha; Walking	2015
Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF). Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Jun-22, Volume: 32, Issue:1 Topics: Administration, Inhalation; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Interferon-gamma; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Pulmonary Diffusing Capacity; Pyridones; Recombinant Proteins; Reference Values; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Treatment Outcome	2015
Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine, 2015, Volume: 94, Issue:42 Topics: Asian People; Double-Blind Method; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2015
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2016, 09-15, Volume: 194, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Models, Statistical; Proportional Hazards Models; Pyridones; Risk Assessment; Risk Factors; Surveys and Questionnaires; Vital Capacity	2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, Volume: 71, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Pyridones; Research Design; Treatment Outcome; Vital Capacity	2016
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:6 Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Therapy, Combination; Europe; Expectorants; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome	2016
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respiratory research, 2016, 07-22, Volume: 17, Issue:1 Topics: Administration, Oral; Disease Progression; Drug Administration Schedule; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Pneumonectomy; Pyridones; Risk Factors; Time Factors; Treatment Outcome	2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. The European respiratory journal, 2016, Volume: 48, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Respiratory Function Tests; Surveys and Questionnaires; Tidal Volume; Treatment Outcome; Vital Capacity	2016
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, Volume: 72, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Risk Factors; Treatment Outcome	2017
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Treatment Outcome	2017
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:3-b Suppl Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Internationality; Life Expectancy; Male; Middle Aged; Predictive Value of Tests; Pyridones; Survival Rate; Treatment Outcome	2017
Pirfenidone in idiopathic pulmonary fibrosis. The European respiratory journal, 2010, Volume: 35, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Oximetry; Patient Compliance; Placebo Effect; Pyridones; Treatment Outcome; Vital Capacity; Young Adult	2010
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Male; Middle Aged; Pyridones; Vital Capacity	2011
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respiratory research, 2011, Jul-15, Volume: 12 Topics: Aged; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Idiopathic Pulmonary Fibrosis; Japan; Kaplan-Meier Estimate; Lung; Middle Aged; Pyridones; Respiratory System Agents; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vital Capacity	2011
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert review of respiratory medicine, 2011, Volume: 5, Issue:4 Topics: Australia; Double-Blind Method; Europe; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mexico; North America; Pyridones; Respiratory System Agents; Time Factors; Treatment Outcome; Vital Capacity	2011
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respiratory research, 2011, Oct-28, Volume: 12 Topics: Adult; Aged; Double-Blind Method; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity; Young Adult	2011
CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. European journal of radiology, 2014, Volume: 83, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pyridones; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome	2014

Other Studies

293 other study(ies) available for pirfenidone and Cryptogenic Fibrosing Alveolitis

Article	Year
Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones. European journal of medicinal chemistry, 2016, Apr-13, Volume: 112 Topics: Amination; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Imines; Lung; Models, Molecular; Superoxides; Thiazolidines	2016
Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation Journal of medicinal chemistry, 2017, 05-11, Volume: 60, Issue:9 Topics: Animals; Humans; Idiopathic Pulmonary Fibrosis; Imidazoles; Mice; Mice, Knockout; Phosphoric Diester Hydrolases; Pyrimidines; Rats	2017
Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. Journal of medicinal chemistry, 2019, 10-10, Volume: 62, Issue:19 Topics: Animals; Bleomycin; Cell Line; Cell Proliferation; Crystallography, X-Ray; Drug Evaluation, Preclinical; Half-Life; Humans; Idiopathic Pulmonary Fibrosis; Isoenzymes; Lung; Mice; Mice, Inbred ICR; Molecular Conformation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Quinazolines; Signal Transduction; Structure-Activity Relationship	2019
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorganic & medicinal chemistry, 2020, 01-15, Volume: 28, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Janus Kinase 3; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship	2020
Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. Journal of medicinal chemistry, 2020, 07-23, Volume: 63, Issue:14 Topics: Animals; Bleomycin; Cell Differentiation; Cyclic Nucleotide Phosphodiesterases, Type 1; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Molecular Structure; Myofibroblasts; Phosphodiesterase Inhibitors; Protein Binding; Pyrazoles; Pyrimidinones; Rats, Sprague-Dawley; Structure-Activity Relationship; Thermodynamics	2020
Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of medicinal chemistry, 2021, 05-13, Volume: 64, Issue:9 Topics: Animals; CHO Cells; Cricetulus; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-8; Male; Mice; Pyridazines; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship; Tissue Distribution	2021
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12 Topics: Animals; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Idiopathic Pulmonary Fibrosis; Nimodipine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats	2022
Discovery of a novel Pleuromutilin derivative as anti-IPF lead compound via high-throughput assay. European journal of medicinal chemistry, 2022, Nov-05, Volume: 241 Topics: Animals; Bleomycin; Diterpenes; Fibroblasts; High-Throughput Screening Assays; Idiopathic Pulmonary Fibrosis; Lung; Mice; Mice, Inbred C57BL; NIH 3T3 Cells; Pleuromutilins; Polycyclic Compounds; Transforming Growth Factor beta1	2022
Uniportal video-assisted thoracic surgery and perioperative pirfenidone for lung cancer and idiopathic pulmonary fibrosis: a case report. The Journal of international medical research, 2021, Volume: 49, Issue:9 Topics: Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Neoplasm Recurrence, Local; Pyridones; Thoracic Surgery, Video-Assisted	2021
Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting Turkish journal of medical sciences, 2021, 12-13, Volume: 51, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Tablets; Treatment Outcome	2021
Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. International journal of clinical practice, 2021, Volume: 75, Issue:12 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Artificial Intelligence; COVID-19; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity	2021
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Respiratory research, 2021, Oct-19, Volume: 22, Issue:1 Topics: Aged; Aged, 80 and over; Ambulatory Care; Antifibrotic Agents; Drug Costs; Female; Hospital Costs; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2021
Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia. Australian health review : a publication of the Australian Hospital Association, 2021, Volume: 45, Issue:6 Topics: Australia; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2021
Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:20 Topics: Aged; Aged, 80 and over; Antifibrotic Agents; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Prospective Studies; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity	2021
Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort. Advances in therapy, 2022, Volume: 39, Issue:1 Topics: Cohort Studies; France; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pyridones; Tablets; Treatment Outcome	2022
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. Internal and emergency medicine, 2022, Volume: 17, Issue:3 Topics: Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2022
Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period. Respiratory medicine, 2021, Volume: 190 Topics: Aged; Antifibrotic Agents; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Transplantation; Male; Perioperative Period; Pyridones; Retrospective Studies; Vital Capacity; Waiting Lists; Weight Loss	2021
The antifibrotic effect of pheretima protein is mediated by the TGF-β1/Smad2/3 pathway and attenuates inflammation in bleomycin-induced idiopathic pulmonary fibrosis. Journal of ethnopharmacology, 2022, Mar-25, Volume: 286 Topics: Animals; Anti-Inflammatory Agents; Bleomycin; Disease Models, Animal; Freeze Drying; Idiopathic Pulmonary Fibrosis; Inflammation; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Oligochaeta; Proteins; Pyridones; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1	2022
Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study. PloS one, 2021, Volume: 16, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Body Mass Index; Disease-Free Survival; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Respiratory Function Tests; Retrospective Studies; Risk Factors; Survival Rate	2021
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States. BMC pulmonary medicine, 2022, Jan-10, Volume: 22, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Cost of Illness; Cost-Benefit Analysis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Markov Chains; Protein Kinase Inhibitors; Pyridones; United States	2022
Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells, 2022, 01-02, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prognosis; Pyridones; Treatment Outcome	2022
Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison. European journal of hospital pharmacy : science and practice, 2023, Volume: 30, Issue:2 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2023
Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs. Scientific reports, 2022, 02-23, Volume: 12, Issue:1 Topics: Adaptor Proteins, Vesicular Transport; Antifibrotic Agents; Cadherins; Cell Adhesion Molecule-1; Computational Biology; Extracellular Matrix Proteins; Female; Gene Expression Regulation; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Interleukins; Male; Membrane Proteins; Nerve Tissue Proteins; Pyridones; Racemases and Epimerases; Repressor Proteins; Tensins; Transforming Growth Factor beta	2022
[Desensitization to pirfenidone. Report of one case]. Revista medica de Chile, 2021, Volume: 149, Issue:10 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2021
Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. Respiratory research, 2022, May-28, Volume: 23, Issue:1 Topics: Asbestosis; Humans; Idiopathic Pulmonary Fibrosis; Prospective Studies; Pyridones; Treatment Outcome	2022
Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management. Annals of the American Thoracic Society, 2022, Volume: 19, Issue:6 Topics: Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2022
Desensitization to Pirfenidone in a Patient Diagnosed With Idiopathic Pulmonary Fibrosis and Hypersensitivity to Antifibrotic Drugs. Archivos de bronconeumologia, 2022, Volume: 58, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2022
Role of transient receptor potential vanilloid 4 in therapeutic antifibrotic effects of pirfenidone. American journal of physiology. Lung cellular and molecular physiology, 2022, 08-01, Volume: 323, Issue:2 Topics: Animals; Antineoplastic Agents; Bleomycin; Humans; Idiopathic Pulmonary Fibrosis; Ligands; Lung; Mice; Pyridones; TRPV Cation Channels	2022
Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients. Pulmonary pharmacology & therapeutics, 2022, Volume: 76 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2022
Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PloS one, 2022, Volume: 17, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Lung; Probability; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2022
Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study. The journal of the Royal College of Physicians of Edinburgh, 2022, Volume: 52, Issue:2 Topics: Adult; C-Reactive Protein; COVID-19 Drug Treatment; Ferritins; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Middle Aged; Prednisolone; Pyridones; Treatment Outcome	2022
Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone. Scientific reports, 2022, 10-17, Volume: 12, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Carbon Monoxide; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss	2022
Inhaled deep eutectic solvent based-nanoemulsion of pirfenidone in idiopathic pulmonary fibrosis. Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 352 Topics: Animals; Deep Eutectic Solvents; Idiopathic Pulmonary Fibrosis; Pyridones; Rats; Spectroscopy, Fourier Transform Infrared; X-Ray Microtomography	2022
Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory medicine and research, 2023, Volume: 83 Topics: Delivery of Health Care; Humans; Idiopathic Pulmonary Fibrosis; Indoles	2023
Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis. Scientific reports, 2022, 11-30, Volume: 12, Issue:1 Topics: Animals; Disease Models, Animal; Esomeprazole; Idiopathic Pulmonary Fibrosis; Mice; Prospective Studies; Proton Pump Inhibitors; Retrospective Studies; Transforming Growth Factor beta	2022
Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. The European respiratory journal, 2023, Volume: 61, Issue:4 Topics: Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Myofibroblasts; Trans-Activators; Transcription Factors	2023
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. PloS one, 2023, Volume: 18, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Tapering; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2023
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. JAMA, 2023, 05-09, Volume: 329, Issue:18 Topics: Administration, Oral; Aged; Clinical Trials, Phase III as Topic; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Respiratory Physiological Phenomena; Respiratory System Agents; Treatment Outcome	2023
Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis. Pediatric pulmonology, 2023, Volume: 58, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones	2023
Diagnostic finding on high-resolution computed tomography (HRCT) predicts a good response to pirfenidone in patients with idiopathic pulmonary fibrosis. Medicine, 2023, May-12, Volume: 102, Issue:19 Topics: Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Retrospective Studies; Tomography, X-Ray Computed	2023
A fibroblastic foci-targeting and hypoxia-cleavable delivery system of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Acta biomaterialia, 2023, 09-01, Volume: 167 Topics: Animals; Fibroblasts; Fibrosis; Idiopathic Pulmonary Fibrosis; Lung; Mice	2023
Effects of comorbid chronic kidney disease on mortality in idiopathic pulmonary fibrosis patients and influence of pirfenidone. Scientific reports, 2023, 11-07, Volume: 13, Issue:1 Topics: Comorbidity; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Renal Insufficiency, Chronic; Treatment Outcome	2023
Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis. Medicina (Kaunas, Lithuania), 2019, Aug-06, Volume: 55, Issue:8 Topics: Bias; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Research Design; Treatment Outcome	2019
Improving outcomes and managing costs in idiopathic pulmonary fibrosis. The American journal of managed care, 2019, Volume: 25, Issue:11 Suppl Topics: Antineoplastic Agents; Chronic Disease; Comorbidity; Cost of Illness; Health Expenditures; Health Resources; Health Services; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medication Adherence; Patient Care Management; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Quality of Life; Registries	2019
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients. Lung, 2019, Volume: 197, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Gastrointestinal Diseases; Health Care Surveys; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Netherlands; Pyridones; Risk Assessment; Risk Factors; Self Report; Time Factors; Treatment Outcome	2019
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respiratory medicine, 2019, Volume: 156 Topics: Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Retrospective Studies; Vital Capacity	2019
Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory investigation, 2019, Volume: 57, Issue:6 Topics: Humans; Idiopathic Pulmonary Fibrosis; Prognosis; Pyridones; Vital Capacity	2019
[The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2019, Sep-12, Volume: 42, Issue:9 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome	2019
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust. BMC pulmonary medicine, 2019, Sep-05, Volume: 19, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dust; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Male; Middle Aged; Multivariate Analysis; Occupational Exposure; Prognosis; Prospective Studies; Pyridones; Regression Analysis; Respiratory Function Tests; Treatment Outcome	2019
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Respiratory research, 2019, Sep-11, Volume: 20, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Female; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Interferon-gamma; Lung; Male; Pyridones; Young Adult	2019
Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis. Pulmonary pharmacology & therapeutics, 2019, Volume: 59 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyridones; Severity of Illness Index; Weight Loss	2019
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respiratory medicine, 2019, Volume: 159 Topics: Carbon Monoxide; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Time Factors; Vital Capacity	2019
Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surgery today, 2020, Volume: 50, Issue:5 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Perioperative Care; Postoperative Period; Pyridones; Retrospective Studies; Treatment Outcome	2020
Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis. Pharmaceutical research, 2019, Dec-10, Volume: 37, Issue:1 Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Idiopathic Pulmonary Fibrosis; Lung; Lymph; Pyridones; Sheep	2019
Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. PloS one, 2020, Volume: 15, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Carbon Monoxide; China; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity	2020
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC pulmonary medicine, 2020, Jan-31, Volume: 20, Issue:1 Topics: Aged; Biomarkers; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Middle Aged; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2020
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respiratory research, 2020, Feb-10, Volume: 21, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Foundations; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Participation; Protein Kinase Inhibitors; Pyridones; Registries; United States	2020
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory investigation, 2020, Volume: 58, Issue:3 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Predictive Value of Tests; Pyridones; Radiographic Image Enhancement; Retrospective Studies; Tomography, X-Ray Computed; Vital Capacity	2020
Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis. Surgery today, 2020, Volume: 50, Issue:8 Topics: Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Negative Results; Patient Selection; Perioperative Care; Postoperative Complications; Prognosis; Pyridones; Survival Rate	2020
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology (Carlton, Vic.), 2020, Volume: 25, Issue:11 Topics: Antineoplastic Agents; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Longitudinal Studies; Male; Middle Aged; Mortality; Practice Patterns, Physicians'; Pyridones; Treatment Outcome	2020
Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. Advances in therapy, 2020, Volume: 37, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Product Surveillance, Postmarketing; Pyridones; Republic of Korea; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome	2020
Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. Nature communications, 2020, 04-24, Volume: 11, Issue:1 Topics: Adult; Aged; Animals; Biopsy; Disease Models, Animal; Epithelial Cells; Epithelial Sodium Channels; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mice; Mice, Knockout; Middle Aged; Mucin-5B; Nedd4 Ubiquitin Protein Ligases; Proteomics; Pyridones; Ubiquitination	2020
A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC pulmonary medicine, 2020, May-04, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Medication Adherence; Middle Aged; Poland; Pyridones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; Walk Test	2020
The world is not enough - the value of increasing registry data in idiopathic pulmonary fibrosis. Respiratory research, 2020, 05-06, Volume: 21, Issue:1 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Registries; United States	2020
Volume-assured pressure support mode plus pirfenidone as resuscitation therapy in patients with exacerbation of idiopathic pulmonary fibrosis. Advances in respiratory medicine, 2020, Volume: 88, Issue:2 Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Female; Humans; Idiopathic Pulmonary Fibrosis; Noninvasive Ventilation; Pyridones; Treatment Outcome; Vital Capacity	2020
Idiopathic pulmonary fibrosis: Significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines. Respiratory medicine and research, 2020, Volume: 77 Topics: Aged; Aged, 80 and over; Cohort Studies; Diagnostic Techniques, Respiratory System; Female; France; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Internationality; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyridones; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2020
Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, Volume: 158, Issue:4 Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Survival Rate	2020
Photobiological study in pirfenidone-induced photosensitivity. Photodermatology, photoimmunology & photomedicine, 2020, Volume: 36, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Phototoxic; Erythema; Female; Humans; Idiopathic Pulmonary Fibrosis; Pruritus; Pyridones; Sunlight	2020
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study. BMC pulmonary medicine, 2020, Jul-11, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Comparative Effectiveness Research; Female; Health Care Costs; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Medicare; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; United States	2020
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC pulmonary medicine, 2020, Jul-14, Volume: 20, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Consensus; Delphi Technique; Disease Management; Drug-Related Side Effects and Adverse Reactions; Humans; Idiopathic Pulmonary Fibrosis; Practice Patterns, Physicians'; Pyridones; Treatment Outcome	2020
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Thorax, 2020, Volume: 75, Issue:9 Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Proliferation; Cell Survival; Chemokine CCL2; Coculture Techniques; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mast Cells; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridones; Rats; Recombinant Proteins; Signal Transduction; Stem Cell Factor; Vital Capacity	2020
Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, Volume: 159, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Pharmacological; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Lung; Male; Patient Acuity; Positron Emission Tomography Computed Tomography; Prognosis; Pyridones; Receptors, CXCR4; Up-Regulation	2021
Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis. Journal of comparative effectiveness research, 2020, Volume: 9, Issue:13 Topics: Aged; Aged, 80 and over; Comparative Effectiveness Research; Delivery of Health Care; Female; Health Care Costs; Health Services; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Medicare; Patient Acceptance of Health Care; Pyridones; Retrospective Studies; Treatment Outcome; United States	2020
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. Journal of pharmacokinetics and pharmacodynamics, 2021, Volume: 48, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Longitudinal Studies; Lung; Male; Middle Aged; Models, Biological; Prognosis; Pyridones; Respiratory Function Tests; Risk Factors; Smoking; Time Factors; Treatment Outcome; Vital Capacity	2021
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Thoracic cancer, 2020, Volume: 11, Issue:11 Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Pyridones; Retrospective Studies	2020
Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis. European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Exercise Test; Fatigue; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Myalgia; Pyridones; Retrospective Studies; Treatment Outcome	2020
Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined with Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2021, Feb-15, Volume: 60, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cyclosporine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Neoplasms; Male; Pyridones; Treatment Outcome	2021
Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosis-like lesions and nonspecific interstitial pneumonia. The clinical respiratory journal, 2021, Volume: 15, Issue:3 Topics: Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Pyridones; Retrospective Studies	2021
A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2020, Volume: 37, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Prospective Studies; Pyridones; Recovery of Function; Treatment Outcome; Vital Capacity	2020
Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2020, Volume: 37, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; England; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pyridones; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Vital Capacity	2020
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis. International journal of molecular sciences, 2020, Nov-08, Volume: 21, Issue:21 Topics: Animals; Apoptosis; Bleomycin; Capillaries; Dicarboxylic Acids; Endothelial Cells; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mice; Mice, Inbred C57BL; Pyridones; Regeneration	2020
Positive photopatch test to pirfenidone. Contact dermatitis, 2021, Volume: 84, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Photoallergic; Humans; Idiopathic Pulmonary Fibrosis; Male; Patch Tests; Pyridones	2021
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. The European respiratory journal, 2021, Volume: 57, Issue:2 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Mutation; Pyridones; Telomere; Treatment Outcome	2021
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Scientific reports, 2020, 12-04, Volume: 10, Issue:1 Topics: Aged; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspepsia; Female; Hospitals, University; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Nausea; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity	2020
Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury. Journal of cardiovascular pharmacology, 2021, 03-01, Volume: 77, Issue:3 Topics: Animals; Drug Repositioning; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; MicroRNAs; Myocardial Reperfusion Injury; Protein Kinase Inhibitors; Pyridones; Signal Transduction; src-Family Kinases; ST Elevation Myocardial Infarction	2021
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology, 2020, 09-22, Volume: 9, Issue:1 Topics: Animals; B7-H1 Antigen; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Mice; Pyridones	2020
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, Volume: 18, Issue:7 Topics: Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Medicare; Pharmaceutical Preparations; Pyridones; Retrospective Studies; Treatment Outcome; United States	2021
Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2. American journal of respiratory and critical care medicine, 2021, 02-01, Volume: 203, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones	2021
Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease. Respiratory investigation, 2021, Volume: 59, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2021
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis. American journal of respiratory cell and molecular biology, 2021, Volume: 64, Issue:6 Topics: Antigens; B-Lymphocytes; Cell Aggregation; Cell Movement; Cell Proliferation; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Inflammation Mediators; Interleukin-6; Pneumonia; Pyridones; src-Family Kinases; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2021
Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms. PloS one, 2021, Volume: 16, Issue:3 Topics: Biomarkers; Chemokines; Cluster Analysis; Cohort Studies; Epithelium; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Idiopathic Pulmonary Fibrosis; Ligands; Lung; Machine Learning; Myeloid Cells; Myocytes, Smooth Muscle; Pericytes; Pyridones; Receptors, Cell Surface; Single-Cell Analysis	2021
Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed. The Lancet. Respiratory medicine, 2021, Volume: 9, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Early Termination of Clinical Trials; Endpoint Determination; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Intention to Treat Analysis; Lung Diseases, Interstitial; Patient Selection; Practice Guidelines as Topic; Pyridones; Respiratory Function Tests	2021
The role of pirfenidone in the treatment of interstitial pneumonia with autoimmune features. Clinical and experimental rheumatology, 2022, Volume: 40, Issue:3 Topics: Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pyridones; Retrospective Studies; Vital Capacity	2022
Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: Propensity score-matched analysis using a nationwide database in Japan. Respirology (Carlton, Vic.), 2021, Volume: 26, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Hospital Mortality; Humans; Idiopathic Pulmonary Fibrosis; Japan; Propensity Score; Pyridones; Treatment Outcome	2021
Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. Journal of pharmacy practice, 2022, Volume: 35, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies; Treatment Outcome	2022
Preoperative pirfenidone in idiopathic pulmonary fibrosis: A wound and injury enigma. Respirology (Carlton, Vic.), 2021, Volume: 26, Issue:6 Topics: Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2021
Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study. BMC pulmonary medicine, 2021, May-03, Volume: 21, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antineutrophil Cytoplasmic; Carbon Monoxide; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pulmonary Diffusing Capacity; Pyridones; Republic of Korea; Retrospective Studies; Treatment Outcome; Vital Capacity	2021
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory research, 2021, May-04, Volume: 22, Issue:1 Topics: Aged; Aged, 80 and over; Databases, Factual; Disease Progression; Female; France; Health Status; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Respiratory System Agents; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2021
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respiratory investigation, 2021, Volume: 59, Issue:6 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Pyridones; Retrospective Studies; Treatment Outcome	2021
Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs. Methods in molecular biology (Clifton, N.J.), 2021, Volume: 2299 Topics: Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lab-On-A-Chip Devices; Models, Biological; Pyridones	2021
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC pulmonary medicine, 2021, Jul-10, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Middle Aged; Pyridones; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Vital Capacity; Walk Test	2021
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC pulmonary medicine, 2021, Jul-12, Volume: 21, Issue:1 Topics: Aged; Disease Progression; Drug Administration Schedule; Drug Substitution; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Prognosis; Propensity Score; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2021
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC pulmonary medicine, 2021, Jul-17, Volume: 21, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cohort Studies; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Middle Aged; Mortality; Propensity Score; Protein Kinase Inhibitors; Pyridones; Treatment Outcome; United States	2021
Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology (Carlton, Vic.), 2021, Volume: 26, Issue:10 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Vital Capacity	2021
Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study. The Korean journal of internal medicine, 2022, Volume: 37, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2022
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology (Carlton, Vic.), 2017, Volume: 22, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome	2017
Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). The patient, 2017, Volume: 10, Issue:5 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Atypical Hemolytic Uremic Syndrome; Female; Humans; Idiopathic Pulmonary Fibrosis; Interviews as Topic; Male; Middle Aged; Netherlands; Orphan Drug Production; Patient Preference; Patient Satisfaction; Psychometrics; Pyridones; Quality of Life; Reproducibility of Results; Retrospective Studies; Surveys and Questionnaires	2017
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, Volume: 14, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vital Capacity	2017
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration; international review of thoracic diseases, 2017, Volume: 93, Issue:6 Topics: Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Disease Progression; Exercise Tolerance; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mortality; Proton Pump Inhibitors; Pyridones; Respiratory Function Tests; Survival Rate; Vital Capacity; Walk Test	2017
Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study. Respiratory medicine, 2017, Volume: 126 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Recombinant Proteins; Retrospective Studies; Risk Factors; Survival Analysis; Thrombomodulin; Treatment Outcome; Vital Capacity	2017
Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world. Respirology (Carlton, Vic.), 2017, Volume: 22, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Fibrosis; Pyridones	2017
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2017, 09-15, Volume: 196, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Double-Blind Method; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity	2017
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment. Chest, 2017, Volume: 151, Issue:5 Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Early Diagnosis; Early Medical Intervention; Enzyme Inhibitors; Health Behavior; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Patient-Centered Care; Precision Medicine; Prognosis; Pyridones; Tomography, X-Ray Computed	2017
The Influence of Sex on Prognosis of Patients With Idiopathic Pulmonary Fibrosis in a Retrospective Cohort. Archivos de bronconeumologia, 2017, Volume: 53, Issue:11 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung Transplantation; Male; Prognosis; Pyridones; Retrospective Studies; Sex Factors	2017
New treatment directions for IPF: current status of ongoing and upcoming clinical trials. Expert review of respiratory medicine, 2017, Volume: 11, Issue:7 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2017
Idiopathic Pulmonary Fibrosis: A Case Discussion. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2017, Jul-01, Volume: 32, Issue:7 Topics: Aged; Drug Interactions; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pharmacists; Professional Role; Pyridones	2017
Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology (Carlton, Vic.), 2017, Volume: 22, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Comorbidity; Disease Progression; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; New Zealand; Pulmonary Medicine; Pyridones; Randomized Controlled Trials as Topic; Societies, Medical	2017
Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World". Respiration; international review of thoracic diseases, 2017, Volume: 94, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Vital Capacity	2017
The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia. The clinical respiratory journal, 2018, Volume: 12, Issue:4 Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Japan; Male; Prognosis; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Necrosis Factor-alpha	2018
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC pulmonary medicine, 2017, Sep-15, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Europe; Female; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Severity of Illness Index; Surveys and Questionnaires; Vital Capacity	2017
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory medicine, 2017, Volume: 131 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Disease-Free Survival; Female; Humans; Idiopathic Pulmonary Fibrosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein D; Pyridones; Retrospective Studies; Survival Rate; Treatment Outcome; Vital Capacity	2017
Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis: a case series. The British journal of dermatology, 2018, Volume: 178, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Dermatitis, Phototoxic; Drug Eruptions; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones	2018
Evaluating new treatment options. The American journal of managed care, 2017, Volume: 23, Issue:11 Suppl Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung; Male; Middle Aged; Pyridones; United States	2017
Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis? American journal of respiratory and critical care medicine, 2018, 02-01, Volume: 197, Issue:3 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2018
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. The European respiratory journal, 2017, Volume: 50, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antitussive Agents; Cough; Diagnostic Self Evaluation; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Prospective Studies; Pyridones; Respiratory Function Tests; Treatment Outcome	2017
The curse of idiopathic. Journal of inherited metabolic disease, 2018, Volume: 41, Issue:1 Topics: Clinical Decision-Making; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Off-Label Use; Patient Selection; Pyridones; Risk Factors; Terminology as Topic; United States; United States Food and Drug Administration	2018
Pirfenidone-induced phototoxic reaction in a patient with idiopathic pulmonary fibrosis. European journal of dermatology : EJD, 2017, 10-01, Volume: 27, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Phototoxic; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Sunlight; Treatment Outcome	2017
Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis. Revista espanola de anestesiologia y reanimacion, 2018, Volume: 65, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Fibroblasts; Hemodynamics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Intraoperative Complications; Multicenter Studies as Topic; Perioperative Care; Postoperative Complications; Preanesthetic Medication; Pyridones; Vital Capacity	2018
Pirfenidone-induced hyponatraemia: insight in mechanism, risk factor and management. BMJ case reports, 2017, Nov-27, Volume: 2017 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Female; Humans; Hyponatremia; Idiopathic Pulmonary Fibrosis; Inappropriate ADH Syndrome; Indoles; Male; Pyridones; Retrospective Studies; Risk Factors	2017
Letter to the Editor: Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory medicine, 2018, Volume: 145 Topics: Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Surfactant-Associated Protein D; Pyridones; Vital Capacity	2018
Drug-induced lupus erythematosus secondary to pirfenidone. The British journal of dermatology, 2018, Volume: 178, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Eruptions; Female; Humans; Idiopathic Pulmonary Fibrosis; Lupus Erythematosus, Systemic; Middle Aged; Pyridones	2018
Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory investigation, 2018, Volume: 56, Issue:1 Topics: Aged; Antineoplastic Agents; Emphysema; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyridones; Retrospective Studies; Risk; Vital Capacity	2018
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017. Pneumologie (Stuttgart, Germany), 2018, Volume: 72, Issue:2 Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides	2018
Health economic evaluation in idiopathic pulmonary fibrosis in France. Current medical research and opinion, 2018, Volume: 34, Issue:10 Topics: Cost-Benefit Analysis; Disease Progression; Female; France; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Quality of Life; Quality-Adjusted Life Years; Respiratory System Agents; Treatment Outcome	2018
Idiopathic pulmonary fibrosis: A guide for nurse practitioners. The Nurse practitioner, 2018, May-17, Volume: 43, Issue:5 Topics: Clinical Trials as Topic; Disease Management; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Nurse Practitioners; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Respiratory System Agents; Self-Management; Tomography, X-Ray Computed	2018
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype. Respirology (Carlton, Vic.), 2018, Volume: 23, Issue:8 Topics: Actins; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Culture Media, Conditioned; Drug Combinations; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Laminin; Phenotype; Phosphorylation; Primary Cell Culture; Proteoglycans; Pyridones; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor; Transforming Growth Factor beta	2018
Does pirfenidone have anticancer effects in patients with idiopathic pulmonary fibrosis? Respiratory investigation, 2018, Volume: 56, Issue:2 Topics: Antineoplastic Agents; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Lung Neoplasms; Male; Prognosis; Pyridones	2018
A rare case of drug-induced hypersensitivity syndrome by pirfenidone for idiopathic pulmonary fibrosis. Allergology international : official journal of the Japanese Society of Allergology, 2018, Volume: 67, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Drug Hypersensitivity Syndrome; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Skin	2018
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. Scientific reports, 2018, 04-13, Volume: 8, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyridones; Treatment Outcome; Vital Capacity	2018
Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report. The Permanente journal, 2018, Volume: 22 Topics: Histiocytoma, Malignant Fibrous; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2018
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC pulmonary medicine, 2018, Apr-27, Volume: 18, Issue:1 Topics: A549 Cells; Alveolar Epithelial Cells; Biomarkers; Cell Movement; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Idiopathic Pulmonary Fibrosis; Myofibroblasts; Pyridones; Sirolimus; Transforming Growth Factor beta1	2018
Chitosan-alginate nano-carrier for transdermal delivery of pirfenidone in idiopathic pulmonary fibrosis. International journal of biological macromolecules, 2018, Oct-15, Volume: 118, Issue:Pt A Topics: Administration, Cutaneous; Alginates; Animals; Chitosan; Drug Carriers; Glucuronic Acid; Hexuronic Acids; Humans; Idiopathic Pulmonary Fibrosis; Mice; Pyridones; Skin	2018
[Real-life experience with pirfenidone in idiopathic pulmonary fibrosis]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2018, May-12, Volume: 41, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2018
[Leukocytosis during pirfenidone therapy: A case report]. Therapie, 2018, Volume: 73, Issue:6 Topics: Aged; Humans; Idiopathic Pulmonary Fibrosis; Leukocytosis; Male; Pyridones	2018
The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2018, Oct-01, Volume: 57, Issue:19 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2018
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. The European respiratory journal, 2018, Volume: 52, Issue:2 Topics: Animals; Cell Differentiation; Disease Progression; Female; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Myofibroblasts; Pulmonary Fibrosis; Pyridones; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Transforming Growth Factor beta1	2018
A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts. Molecular biology of the cell, 2018, 09-01, Volume: 29, Issue:18 Topics: Cell Line; Down-Regulation; Extracellular Matrix; Fibroblasts; Guanine Nucleotide Exchange Factors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Phenotype; Pyridones; Repressor Proteins; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2018
Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2018, 10-15, Volume: 198, Issue:8 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2018
Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2018, 10-15, Volume: 198, Issue:8 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2018
Real-Life Experience with Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study. Archivos de bronconeumologia, 2019, Volume: 55, Issue:2 Topics: Aged; Argentina; Asthenia; Clinical Trials, Phase III as Topic; Exanthema; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Nausea; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Vital Capacity	2019
Gazing into the crystal ball: can treatment response be predicted in IPF? The Lancet. Respiratory medicine, 2018, Volume: 6, Issue:8 Topics: Biomarkers; Humans; Idiopathic Pulmonary Fibrosis; Prognosis; Pyridones	2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. The Lancet. Respiratory medicine, 2018, Volume: 6, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Clinical Trials as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Proportional Hazards Models; Pyridones	2018
Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI. The European respiratory journal, 2018, Volume: 52, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Metabolic Networks and Pathways; Mice; Mice, Inbred C57BL; Proof of Concept Study; Pyridones; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution	2018
Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib. Histopathology, 2019, Volume: 74, Issue:2 Topics: Aged; Alveolar Epithelial Cells; Cell Line, Tumor; Female; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Pyridones	2019
Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. The European respiratory journal, 2018, Volume: 52, Issue:5 Topics: Adult; Aged; Cell Movement; Cell Proliferation; Down-Regulation; Extracellular Matrix; Female; Fibroblasts; Gene Expression Profiling; Gene Ontology; Humans; Hyaluronoglucosaminidase; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Proteins; Pyridones; Transcriptome	2018
[The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2016, Volume: 105, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones	2016
Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Respiratory research, 2018, Sep-15, Volume: 19, Issue:1 Topics: Alveolar Epithelial Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Culture Techniques; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mice; Mice, Inbred C57BL; Pyridones	2018
Pirfenidone-Induced Sarcoid-Like Reaction: A Novel Complication. Chest, 2018, Volume: 154, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Lymphatic Diseases; Male; Middle Aged; Pyridones; Sarcoidosis, Pulmonary	2018
[Pirfenidone (Esbriet Annales de dermatologie et de venereologie, 2018, Volume: 145, Issue:12 Topics: Dermatitis, Phototoxic; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2018
New era of Idiopathic Pulmonary Fibrosis. Respiratory investigation, 2018, Volume: 56, Issue:6 Topics: Biomarkers; Cell- and Tissue-Based Therapy; Female; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Mesenchymal Stem Cells; Pyridones; Respiratory Function Tests	2018
Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Pulmonary pharmacology & therapeutics, 2018, Volume: 53 Topics: Animals; Bleomycin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; p38 Mitogen-Activated Protein Kinases; Pyridones; Rats; Rats, Sprague-Dawley; Smad3 Protein; Transforming Growth Factor beta1	2018
Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients. Oxidative medicine and cellular longevity, 2018, Volume: 2018 Topics: Aged; Antioxidants; Cell Proliferation; Collagen Type I; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species	2018
Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis. Archivos de bronconeumologia, 2019, Volume: 55, Issue:2 Topics: Argentina; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies	2019
Antifibrotics: Shrinking the Box of Therapeutic Uncertainty. Respiration; international review of thoracic diseases, 2019, Volume: 97, Issue:3 Topics: Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Uncertainty	2019
Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles. The European respiratory journal, 2018, Volume: 52, Issue:5 Topics: Fibroblasts; Gene Expression Profiling; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2018
Pirfenidone improves survival in IPF: results from a real-life study. BMC pulmonary medicine, 2018, Nov-23, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Greece; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Vital Capacity	2018
Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PloS one, 2018, Volume: 13, Issue:11 Topics: Apoptosis; Cell Proliferation; Cell Survival; Down-Regulation; Endoplasmic Reticulum Stress; Extracellular Matrix Proteins; Female; Fibroblasts; Histone Deacetylase Inhibitors; Histones; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Panobinostat; Primary Cell Culture; Protective Agents; Pyridones; STAT3 Transcription Factor	2018
Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. Respiratory investigation, 2019, Volume: 57, Issue:2 Topics: Adolescent; Adult; Child; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Male; Middle Aged; Pyridones; Retrospective Studies; Survival Rate; Treatment Outcome; Waiting Lists; Young Adult	2019
Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients. Respiratory research, 2019, Jan-15, Volume: 20, Issue:1 Topics: Aged; Animals; Antineoplastic Agents; Female; Fibrosis; Fluorodeoxyglucose F18; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Mice; Mice, Inbred C57BL; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Pyridones	2019
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respiratory research, 2019, Jan-21, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Czech Republic; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Registries; Respiratory Function Tests; Survival Rate; Treatment Outcome; Vital Capacity	2019
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. The clinical respiratory journal, 2019, Volume: 13, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Male; Middle Aged; Mortality; Prognosis; Pyridones; Retrospective Studies; Risk Factors; Sex Factors; Treatment Outcome	2019
Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study. Lung, 2019, Volume: 197, Issue:2 Topics: Aged; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Pyridones; Retrospective Studies; Time Factors; Treatment Outcome	2019
An Atypical Case of Idiopathic Pulmonary Fibrosis in a Patient from Africa. Medicina (Kaunas, Lithuania), 2019, Mar-14, Volume: 55, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Black People; Bronchoscopy; Diagnosis, Differential; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Hospitals, University; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Male; Pyridones; Rare Diseases; Respiratory Function Tests; Smokers; Sweden; Tomography, X-Ray Computed; Treatment Outcome	2019
The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study. Advances in therapy, 2019, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Agents; Cohort Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Pyridones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; Turkey; Vital Capacity	2019
Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea. The New England journal of medicine, 2019, Mar-28, Volume: 380, Issue:13 Topics: Aged; Alveolitis, Extrinsic Allergic; Biopsy; Diagnosis, Differential; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Pyridones; Radiography, Thoracic; Sarcoidosis; Tomography, X-Ray Computed	2019
Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019, Volume: 19, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Female; Follow-Up Studies; Germany; Graft Rejection; Graft Survival; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Lung Transplantation; Male; Middle Aged; Primary Graft Dysfunction; Pyridones; Retrospective Studies; Treatment Outcome	2019
Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis. Respiration; international review of thoracic diseases, 2019, Volume: 98, Issue:1 Topics: Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2019
Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis. BMC pulmonary medicine, 2019, Apr-11, Volume: 19, Issue:1 Topics: Aged; Anorexia; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Logistic Models; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss	2019
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. American journal of respiratory and critical care medicine, 2019, 07-15, Volume: 200, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Approval; Drug Development; Drug Interactions; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Outcome Assessment; Protein Kinase Inhibitors; Pyridones; Quality of Life; Standard of Care; Vital Capacity; Walk Test	2019
Diffuse Alveolar Hemorrhage Following Pirfenidone Initiation. Journal of pharmacy practice, 2020, Volume: 33, Issue:4 Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pyridones	2020
Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels. Medicina (Kaunas, Lithuania), 2019, May-17, Volume: 55, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones	2019
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2019, 07-15, Volume: 200, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Mortality; Propensity Score; Protein Kinase Inhibitors; Pyridones; Treatment Outcome; United States; Young Adult	2019
Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respiratory research, 2019, Jun-17, Volume: 20, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Prospective Studies; Pyridones; Registries; Retrospective Studies; Societies, Medical; Spain	2019
Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol. Medicine, 2019, Volume: 98, Issue:30 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medicine, Chinese Traditional; Meta-Analysis as Topic; Network Meta-Analysis; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Respiratory Function Tests; Severity of Illness Index; Survival Analysis; Systematic Reviews as Topic	2019
The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models. Molecules (Basel, Switzerland), 2019, Jul-31, Volume: 24, Issue:15 Topics: Animals; Biguanides; Bleomycin; Disease Models, Animal; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mice; Pyridones; Republic of Korea	2019
Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis. Drug design, development and therapy, 2019, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Drug Tolerance; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome	2019
Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis. Thorax, 2013, Volume: 68, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Prescription Drugs; Pyridones; Tumor Necrosis Factor-alpha	2013
Pirfenidone for IPF: pro/con debate; the 'con' viewpoint. Thorax, 2013, Volume: 68, Issue:7 Topics: Humans; Idiopathic Pulmonary Fibrosis; Prescription Drugs; Pyridones	2013
[Idiopathic pulmonary fibrosis: treatment with pirfenidone]. Archivos de bronconeumologia, 2012, Volume: 48 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2012
[Patient treated with pirfenidone]. Archivos de bronconeumologia, 2012, Volume: 48 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2012
Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Archivos de bronconeumologia, 2013, Volume: 49, Issue:8 Topics: Acetylcysteine; Biopsy; Bronchoalveolar Lavage Fluid; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Contraindications; Diagnostic Imaging; Disease Progression; Evidence-Based Medicine; Gastroesophageal Reflux; Genetic Therapy; Glucocorticoids; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Incidence; Indoles; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Palliative Care; Prevalence; Prognosis; Pulmonary Emphysema; Pyridones; Risk Factors; Spain	2013
Galecto Biotech. Nature biotechnology, 2013, Volume: 31, Issue:6 Topics: Drug Approval; Drug Industry; Galectin 3; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2013
Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respiratory medicine, 2013, Volume: 107, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Mucin-1; Pulmonary Surfactant-Associated Protein D; Pyridones; Treatment Outcome; Vital Capacity	2013
[Successful resection of lung cancer with idiopathic pulmonary fibrosis treated by pirfenidone during perioperative period]. Kyobu geka. The Japanese journal of thoracic surgery, 2013, Volume: 66, Issue:10 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Perioperative Period; Pyridones	2013
Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Collagen; Fibroblasts; Humans; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Transforming Growth Factor beta1	2013
Idiopathic pulmonary fibrosis. BMJ (Clinical research ed.), 2013, Nov-07, Volume: 347 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Diagnosis, Differential; Humans; Idiopathic Pulmonary Fibrosis; Practice Guidelines as Topic; Pyridones; Treatment Outcome	2013
Combination therapies targeting multiple pathways in idiopathic pulmonary fibrosis (IPF). Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:22 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Vital Capacity	2013
Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:22 Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2013
Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respiratory medicine, 2014, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2014
NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis. The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:3 Topics: Antineoplastic Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Pyridones; State Medicine; United Kingdom; Vital Capacity	2013
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. American journal of respiratory and critical care medicine, 2014, Apr-01, Volume: 189, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Clinical Trials, Phase III as Topic; Feasibility Studies; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Interferon-gamma; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Pyridones; Randomized Controlled Trials as Topic; Recombinant Proteins; Research Design; Sample Size; Treatment Outcome	2014
Evolvement of best practice in diagnosis and management of idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2014, Mar-01, Volume: 23, Issue:131 Topics: Clinical Trials, Phase III as Topic; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Respiratory System Agents	2014
Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respiratory investigation, 2014, Volume: 52, Issue:2 Topics: Aged; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; Female; Histamine H2 Antagonists; Humans; Idiopathic Pulmonary Fibrosis; Logistic Models; Male; Middle Aged; Nausea; Predictive Value of Tests; Proportional Hazards Models; Proton Pump Inhibitors; Pyridones; Retrospective Studies; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome; Vital Capacity	2014
A new hope for idiopathic pulmonary fibrosis. The New England journal of medicine, 2014, May-29, Volume: 370, Issue:22 Topics: Antifibrinolytic Agents; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Protein Kinase Inhibitors; Pyridones	2014
Management of idiopathic pulmonary fibrosis: selected case reports. European respiratory review : an official journal of the European Respiratory Society, 2014, Volume: 23, Issue:132 Topics: Aged; Anti-Inflammatory Agents; Disease Progression; Fatal Outcome; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Predictive Value of Tests; Pyridones; Recovery of Function; Respiratory Function Tests; Risk Factors; Smoking; Smoking Cessation; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2014
InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs. Nature reviews. Drug discovery, 2014, Volume: 13, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Industry; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Tumor Necrosis Factor-alpha	2014
Hot off the breath: A big step forward for idiopathic pulmonary fibrosis. Thorax, 2014, Volume: 69, Issue:9 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic	2014
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration; international review of thoracic diseases, 2014, Volume: 88, Issue:3 Topics: Acetylcysteine; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Expectorants; Fatigue; Female; Gastrointestinal Diseases; Germany; Humans; Idiopathic Pulmonary Fibrosis; Male; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity; Weight Loss	2014
2014 American Thoracic Society International Conference. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Asthma; Congresses as Topic; Eosinophilia; Expectorants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Distress Syndrome	2014
[Idiopathic pulmonary fibrosis: A new era, new challenges]. Revue des maladies respiratoires, 2014, Volume: 31, Issue:7 Topics: Acetylcysteine; Clinical Trials as Topic; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2014
Landmark approvals in idiopathic pulmonary fibrosis. Nature biotechnology, 2014, Volume: 32, Issue:11 Topics: Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; United States; United States Food and Drug Administration	2014
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surgery today, 2015, Volume: 45, Issue:10 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Disease Progression; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyridones; Retrospective Studies; Treatment Outcome	2015
A new era of drug therapy for idiopathic pulmonary fibrosis. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Middle Aged; Pyridones; Randomized Controlled Trials as Topic	2014
Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy. Biopharmaceutics & drug disposition, 2015, Volume: 36, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Membrane Permeability; Idiopathic Pulmonary Fibrosis; Kidney; Liver; Lung; Male; Pyridones; Rats; Tissue Distribution	2015
Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report. Respiratory investigation, 2015, Volume: 53, Issue:1 Topics: Acute-Phase Reaction; Aged, 80 and over; Disease Progression; Drug Therapy, Combination; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Infusions, Intravenous; Lung Neoplasms; Male; Methylprednisolone; Postoperative Complications; Prednisolone; Pulse Therapy, Drug; Pyridones; Treatment Outcome	2015
Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine, 2015, Jan-01, Volume: 191, Issue:1 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Female; Germany; Humans; Idiopathic Pulmonary Fibrosis; Italy; Male; Middle Aged; Pyridones; Retrospective Studies; Total Lung Capacity; Treatment Outcome; Vital Capacity	2015
Novel treatments for idiopathic pulmonary fibrosis. The American journal of medicine, 2015, Volume: 128, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein-Tyrosine Kinases; Pyridones	2015
Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. American journal of respiratory and critical care medicine, 2015, Feb-01, Volume: 191, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2015
Update in diffuse parenchymal lung disease, 2013. American journal of respiratory and critical care medicine, 2015, Feb-01, Volume: 191, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Enzyme Inhibitors; Genomics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Polymorphism, Genetic; Pyridones; Treatment Outcome; United States; United States Food and Drug Administration	2015
Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology (Carlton, Vic.), 2015, Volume: 20, Issue:3 Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2015
[Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time]. MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2 Topics: Acetylcysteine; Disease Progression; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Vital Capacity	2015
Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis. Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:2 Topics: Cell Line; Cell Proliferation; Collagen; Fibroblast Growth Factors; Fibroblasts; HEK293 Cells; Humans; Idiopathic Pulmonary Fibrosis; Liposomes; Lung; Pyridones	2015
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. The New England journal of medicine, 2015, Mar-26, Volume: 372, Issue:13 Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Drug Approval; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; United States; United States Food and Drug Administration; Vital Capacity	2015
[What is new in 2014 for the specialist in hospital internal medicine? The point of view of university hospital chief residents]. Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arterial Pressure; Catheterization, Central Venous; Diverticulitis; Emergency Service, Hospital; Hospitals, University; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Internal Medicine; Kidney; Medical Staff, Hospital; Pneumonia; Pulmonary Embolism; Pyridones; Shock, Septic; Sympathectomy; Tumor Necrosis Factor-alpha; Ultrasonography; Venous Thromboembolism; Vitamin B 12 Deficiency; Vitamin E	2015
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. The European respiratory journal, 2015, Volume: 46, Issue:1 Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Exercise Test; Female; Germany; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyridones; Registries; Steroids; Tomography, X-Ray Computed; Vital Capacity	2015
A combined therapeutic approach in progressive idiopathic pulmonary fibrosis-pirfenidone as bridge therapy for ex vivo lung transplantation: a case report. Transplantation proceedings, 2015, Volume: 47, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Quality of Life	2015
Two therapies now available for idiopathic pulmonary fibrosis. Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Vital Capacity	2014
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respiratory medicine, 2015, Volume: 109, Issue:7 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Italy; Male; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2015
[Two new drugs for the treatment of idiopathic lung fibrosis: A new therapeutic era!]. La Revue de medecine interne, 2015, Volume: 36, Issue:11 Topics: Antineoplastic Agents; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic	2015
Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). PloS one, 2015, Volume: 10, Issue:6 Topics: Aged; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Multidetector Computed Tomography; Pyridones; Retrospective Studies; Treatment Outcome	2015
Pirfenidone-induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis. The Journal of dermatology, 2016, Volume: 43, Issue:2 Topics: Aged; Dermatitis, Phototoxic; Humans; Hyperpigmentation; Idiopathic Pulmonary Fibrosis; Male; Pyridones	2016
An Unusual Case of Hypoxemia Improving Overnight in Idiopathic Pulmonary Fibrosis. Journal of cardiothoracic and vascular anesthesia, 2015, Volume: 29, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Echocardiography, Transesophageal; Foramen Ovale, Patent; Humans; Hypoxia; Idiopathic Pulmonary Fibrosis; Lung; Male; Pyridones; Septal Occluder Device; Tomography, X-Ray Computed	2015
Developments in the management of idiopathic pulmonary fibrosis. Drug and therapeutics bulletin, 2015, Volume: 53, Issue:7 Topics: Disease Progression; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Orphan Drug Production; Pyridones; United Kingdom	2015
Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. Advances in therapy, 2015, Volume: 32, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Netherlands; Pyridones; Respiratory Function Tests; Retrospective Studies; Smoking; Treatment Outcome; Vital Capacity	2015
IPF, comorbidities and management implications: Patient case 2. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Aug-03, Volume: 32 Suppl 1 Topics: Arteriosclerosis; Comorbidity; Denmark; Disease Management; Female; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Middle Aged; Pyridones; Radiography; Refusal to Treat; Respiratory Function Tests; Severity of Illness Index; Smoking	2015
Challenges in IPF diagnosis, current management and future perspectives: Patient case 1. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Aug-03, Volume: 32 Suppl 1 Topics: Aged; Dyspnea; Early Diagnosis; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
Challenges in IPF diagnosis, current management and future perspectives: Patient case 2. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Aug-03, Volume: 32 Suppl 1 Topics: Adrenal Cortex Hormones; Aged; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Eruptions; Follow-Up Studies; Hemoptysis; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Risk Assessment; Severity of Illness Index; Tachycardia, Supraventricular; Tomography, X-Ray Computed; Treatment Outcome	2015
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. The European respiratory journal, 2015, Volume: 46, Issue:3 Topics: Clinical Trials, Phase III as Topic; Data Collection; Data Interpretation, Statistical; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Randomized Controlled Trials as Topic; Respiratory Function Tests; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Survival Rate; Treatment Outcome; Vital Capacity	2015
Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. The European respiratory journal, 2015, Volume: 46, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Body Mass Index; Compassionate Use Trials; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Respiratory Function Tests; Retrospective Studies; Vital Capacity	2015
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respiratory investigation, 2015, Volume: 53, Issue:5 Topics: Aged; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyridones; Severity of Illness Index; Treatment Outcome; Vital Capacity	2015
New guideline on treatment of idiopathic pulmonary fibrosis. The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones	2015
[Idiopathic Pulmonary Fibrosis]. Pneumologie (Stuttgart, Germany), 2015, Volume: 69, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory System Agents; Treatment Outcome	2015
Therapeutic advances in idiopathic pulmonary fibrosis. Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2016
Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan. Respiratory investigation, 2015, Volume: 53, Issue:6 Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Multivariate Analysis; Oxygen Consumption; Proportional Hazards Models; Pulmonary Alveoli; Pyridones; Risk Factors; Vital Capacity	2015
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respiratory investigation, 2015, Volume: 53, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Oxygen Consumption; Pyridones; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome; Vital Capacity; Young Adult	2015
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC medicine, 2015, Nov-09, Volume: 13 Topics: Aged; Aged, 80 and over; Biomarkers; Disease Progression; Endothelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Vascular Endothelial Growth Factor A	2015
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:22 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Carbon Monoxide; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Predictive Value of Tests; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2015
"The Long and Winding Road" seeking specific drugs for idiopathic pulmonary fibrosis. Respiratory investigation, 2016, Volume: 54, Issue:1 Topics: Clinical Trials as Topic; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Pyridones; United States	2016
Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC pulmonary medicine, 2016, Jan-14, Volume: 16 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Attitude to Health; Caregivers; Disease Management; Europe; Female; Germany; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Italy; Male; Nurse's Role; Physician's Role; Pyridones; Qualitative Research; Role; Surveys and Questionnaires; United Kingdom	2016
Idiopathic pulmonary fibrosis: the role of the pharmacy benefit manager in providing access to effective, high-value care. The American journal of managed care, 2015, Volume: 21, Issue:14 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Drug Costs; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Insurance, Pharmaceutical Services; Pharmacies; Pyridones; United States	2015
Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respiratory research, 2016, Feb-04, Volume: 17 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Myofibroblasts; Pyridones; Treatment Outcome	2016
Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idiopathic Pulmonary Fibrosis; Japan; Male; Pyridones; Retrospective Studies; Time Factors; Treatment Outcome; Vital Capacity	2016
A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pleural Diseases; Pyridones; Radiography, Thoracic; Respiratory Physiological Phenomena; Time Factors; Treatment Outcome; Vital Capacity; Weight Loss	2016
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. BMC pulmonary medicine, 2016, Mar-03, Volume: 16 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Vital Capacity	2016
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity	2016
Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Respiration; international review of thoracic diseases, 2016, Volume: 91, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Vital Capacity	2016
Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs & aging, 2016, Volume: 33, Issue:5 Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Biopsy; Comorbidity; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Indoles; Male; Pyridones; Tomography, X-Ray Computed	2016
MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. PloS one, 2016, Volume: 11, Issue:5 Topics: A549 Cells; Animals; Bleomycin; Bronchoalveolar Lavage; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Female; HeLa Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Injury; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2016
Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC pulmonary medicine, 2016, May-23, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Belgium; Biomarkers; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Male; Middle Aged; Mucin-1; Prospective Studies; Pyridones	2016
[Idiopatic pulmonary fibrosis - news in multidisciplinary diagnostic and therapeutic approaches]. Ceskoslovenska patologie, 2016, Volume: 52, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Humans; Idiopathic Pulmonary Fibrosis; Prognosis; Pyridones	2016
Pirfenidone inhibits p38-mediated generation of procoagulant microparticles by human alveolar epithelial cells. Pulmonary pharmacology & therapeutics, 2016, Volume: 39 Topics: A549 Cells; Alveolar Epithelial Cells; Cell-Derived Microparticles; Humans; Hydrogen Peroxide; Idiopathic Pulmonary Fibrosis; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridones	2016
Pirfenidone for Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2016, 08-01, Volume: 194, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2016
COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No. Chest, 2016, Volume: 150, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Decision Making; Drug Tolerance; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Severity of Illness Index; Tumor Necrosis Factor-alpha	2016
POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes. Chest, 2016, Volume: 150, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Decision Making; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Severity of Illness Index; Tumor Necrosis Factor-alpha	2016
Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. The clinical respiratory journal, 2018, Volume: 12, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diagnosis, Differential; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pyridones; Tomography, X-Ray Computed	2018
Eosinophilic pneumonia associated with pirfenidone therapy. The European respiratory journal, 2016, Volume: 48, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Computed Tomography Angiography; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pulmonary Eosinophilia; Pyridones; Tomography, X-Ray Computed	2016
Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, Volume: 13, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2016
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis. The Annals of thoracic surgery, 2016, Volume: 102, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Pneumonectomy; Postoperative Complications; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Smoking	2016
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Respiratory research, 2016, 08-22, Volume: 17, Issue:1 Topics: Animals; Bleomycin; Calcium Signaling; Cell Line; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Profiling; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Pyridones; RGS Proteins; RNA, Messenger; Thrombin; Time Factors; Transfection; Up-Regulation	2016
Respiratory Conditions Update: Restrictive Lung Disease. FP essentials, 2016, Volume: 448 Topics: Anti-Inflammatory Agents, Non-Steroidal; Continuous Positive Airway Pressure; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Obesity Hypoventilation Syndrome; Oxygen Inhalation Therapy; Polysomnography; Pyridones; Respiratory Function Tests; Respiratory Therapy; Sleep Apnea, Obstructive; Weight Loss	2016
Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study. The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5 Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Proton Pump Inhibitors; Pyridones; Treatment Outcome	2016
Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone? Lung, 2017, Volume: 195, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dyspnea; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Pilot Projects; Prospective Studies; Pulmonary Diffusing Capacity; Pyridones; Treatment Outcome; Vital Capacity; Walk Test	2017
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC pulmonary medicine, 2016, 11-18, Volume: 16, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Disease Progression; Female; Graft Survival; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Pyridones; Retrospective Studies; Tertiary Care Centers; Vital Capacity	2016
Pirfenidone and mortality in idiopathic pulmonary fibrosis. The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2017
Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models. Pharmaceutical biology, 2017, Volume: 55, Issue:1 Topics: Acetylcysteine; Animals; Bleomycin; Blotting, Western; Caveolin 1; Cytoprotection; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Idiopathic Pulmonary Fibrosis; Lung; Male; Platelet-Derived Growth Factor; Prednisone; Protective Agents; Pyridones; Rats, Wistar; Real-Time Polymerase Chain Reaction; Signal Transduction; Time Factors; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2017
Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respiratory investigation, 2017, Volume: 55, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mucin-1; Prognosis; Pyridones; Retrospective Studies	2017
3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI insight, 2017, 01-26, Volume: 2, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Case-Control Studies; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Models, Biological; Myofibroblasts; Precision Medicine; Pyridones; Spheroids, Cellular; Transforming Growth Factor beta1	2017
Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:5 Topics: Adult; Aged; Cell Proliferation; Female; Fibroblasts; Hedgehog Proteins; Humans; Idiopathic Pulmonary Fibrosis; Kruppel-Like Transcription Factors; Male; Middle Aged; Nuclear Proteins; Pyridones; Signal Transduction; Transforming Growth Factor beta; Zinc Finger Protein Gli2	2017
A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly. American journal of respiratory cell and molecular biology, 2017, Volume: 57, Issue:1 Topics: Collagen Type I; Down-Regulation; Extracellular Matrix Proteins; Fibrillar Collagens; Fibroblasts; HSP47 Heat-Shock Proteins; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Protein Processing, Post-Translational; Pyridones; Tacrolimus Binding Proteins; Transcription, Genetic	2017
Pirfenidone-induced photo-allergic reaction in a patient with idiopathic pulmonary fibrosis. Photodermatology, photoimmunology & photomedicine, 2017, Volume: 33, Issue:4 Topics: Aged; Dermatitis, Photoallergic; Drug Hypersensitivity; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones	2017
Improving Survival in Idiopathic Pulmonary Fibrosis: The Race Has Just Begun. Chest, 2017, Volume: 151, Issue:3 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Survival Analysis; Tumor Necrosis Factor-alpha	2017
Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Archivos de bronconeumologia, 2017, Volume: 53, Issue:5 Topics: Adrenal Cortex Hormones; Disease Progression; Disease-Free Survival; Evidence-Based Medicine; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Meta-Analysis as Topic; Pulmonary Emphysema; Pyridones; Randomized Controlled Trials as Topic; Societies, Medical; Spain	2017
Permutation test following covariate-adaptive randomization in randomized controlled trials. Journal of biopharmaceutical statistics, 2009, Volume: 19, Issue:1 Topics: Algorithms; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Computer Simulation; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Models, Statistical; Monte Carlo Method; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity	2009
[Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2009, Volume: 134, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Gastrointestinal Diseases; Humans; Idiopathic Pulmonary Fibrosis; Photosensitivity Disorders; Pyridones; Skin Neoplasms	2009
Idiopathic pulmonary fibrosis and pirfenidone. The European respiratory journal, 2010, Volume: 35, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic	2010
FDA panel likes new treatment for idiopathic pulmonary fibrosis. Managed care (Langhorne, Pa.), 2010, Volume: 19, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; United States; United States Food and Drug Administration	2010
Pirfenidone in idiopathic pulmonary fibrosis. The European respiratory journal, 2010, Volume: 36, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Pyridones; Research Design; Time Factors; Treatment Outcome	2010
Pirfenidone for idiopathic pulmonary fibrosis. Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Approval; Endpoint Determination; Europe; Evidence-Based Medicine; Exercise Test; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Vital Capacity	2011
Pirfenidone. Nature reviews. Drug discovery, 2011, Volume: 10, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Approval; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2011
A first step against idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2011, Sep-01, Volume: 20, Issue:121 Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Respiratory System Agents; Treatment Outcome	2011
Idiopathic pulmonary fibrosis: recent milestones in disease management. European respiratory review : an official journal of the European Respiratory Society, 2012, Jun-01, Volume: 21, Issue:124 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2012
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. The clinical respiratory journal, 2012, Volume: 6, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Discovery; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2012
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation? The European respiratory journal, 2012, Volume: 40, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Respiratory Function Tests	2012